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A B S T R A C T
Background
Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. It is associated with lifelongmorbidity and a reduced
life expectancy. Hydroxyurea (hydroxycarbamide), an oral chemotherapeutic drug, ameliorates some of the clinical problems of SCD,
in particular that of pain, by raising fetal haemoglobin. This is an update of a previously published Cochrane Review.
Objectives
To assess the effects of hydroxyurea therapy in people with SCD (all genotypes), of any age, regardless of setting.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Register, comprising of references
identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference
proceedings. We also searched online trial registries.
Date of the most recent search: 16 January 2017.
Selection criteria
Randomised and quasi-randomised controlled trials, of one month or longer, comparing hydroxyurea with placebo, standard therapy
or other interventions for people with SCD.
Data collection and analysis
Authors independently assessed studies for inclusion, carried out data extraction and assessed the risk of bias.
Main results
Seventeen studies were identified in the searches; eight randomised controlled trials were included, recruiting 899 adults and children
with SCD (haemoglobin SS (HbSS), haemoglobin SC (HbSC) or haemoglobin Sβºthalassaemia (HbSβºthal) genotypes). Studies
lasted from six to 30 months.
Four studies (577 adults and children with HbSS or HbSβºthal) compared hydroxyurea to placebo; three recruited individuals with
only severe disease and one recruited individuals with all disease severities. There were statistically significant improvements in terms
of pain alteration (using measures such as pain crisis frequency, duration, intensity, hospital admissions and opoid use), measures of
fetal haemoglobin and neutrophil counts and fewer occurrences of acute chest syndrome and blood transfusions in the hydroxyurea
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groups. There were no consistent statistically significant differences in terms of quality of life and adverse events (including serious or
life-threatening events). Seven deaths occurred during the studies, but the rates by treatment group were not statistically significantly
different.
Two studies (254 children with HbSS or HbSβºthal also with risk of primary or secondary stroke) compared hydroxyurea and
phlebotomy to transfusion and chelation; there were statistically significant improvements in terms of measures of fetal haemoglobin
and neutrophil counts, but more occurrences of acute chest syndrome and infections in the hydroxyurea and phlebotomy group. There
were no consistent statistically significant differences in terms of pain alteration and adverse events (including serious or life-threatening
events). Two deaths occurred during the studies (one in a the hydroxyurea treatment arm and one in the control arm), but the rates by
treatment group were not statistically significantly different. In the primary prevention study, no strokes occurred in either treatment
group but in the secondary prevention study, seven strokes occurred in the hydroxyurea and phlebotomy group (none in the transfusion
and chelation group) and the study was terminated early.
The quality of the evidence for the above two comparisonswas judged asmoderate to low as the studies contributing to these comparisons
were mostly large and well designed (and at low risk of bias); however evidence was limited and imprecise for some outcomes such as
quality of life, deaths during the studies and adverse events and results are applicable only to individuals with HbSS and HbSβºthal
genotypes.
Of the remaining two studies, one (22 children with HbSS or HbSβºthal also at risk of stoke) compared hydroxyurea to observation;
there were statistically significant improvements in terms of measures of fetal haemoglobin and neutrophil counts but no statistically
significant differences in terms of adverse events (including serious or life-threatening events).
The final study (44 adults and children with HbSC) compared treatment regimens with and without hydroxyurea - there was statistically
significant improvement in terms of measures of fetal haemoglobin, but no statistically significant differences in terms of adverse events
(including serious or life-threatening events). No participants died in either of these studies and other outcomes relevant to the review
were not reported.
The quality of the evidence for the above two comparisons was judged to be very low due to the limited number of participants, the
lack of statistical power (as both studies were terminated early with approximately only 20% of their target sample size recruited) and
the lack of applicability to all age groups and genotypes.
Authors’ conclusions
There is evidence to suggest that hydroxyurea is effective in decreasing the frequency of pain episodes and other acute complications in
adults and children with sickle cell anaemia of HbSS or HbSβºthal genotypes and in preventing life-threatening neurological events in
those with sickle cell anaemia at risk of primary stroke by maintaining transcranial doppler velocities. However, there is still insufficient
evidence on the long-term benefits of hydroxyurea, particularly in preventing chronic complications of SCD, recommending a standard
dose or dose escalation to maximum tolerated dose. There is also insufficient evidence about the long-term risks of hydroxyurea,
including its effects on fertility and reproduction. Evidence is also limited on the effects of hydroxyurea on individuals with HbSC
genotype. Future studies should be designed to address such uncertainties.
P L A I N L A N G U A G E S U M M A R Y
Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease
Review question
What is the effect of hydroxyurea on clinical outcomes (changes in pain crises, life-threatening illnesses, survival, haemoglobin levels,
quality of life and side effects) in people with sickle cell disease (SCD) of any genotype?
Background
SCD is an inherited genetic disorder that creates problems with haemoglobin (the substance in red blood cells that carries oxygen around
the body). The disease can be inherited in different ways; people can inherit two sickle genes (HbSS genotype) or they can inherit the
sickle gene from one parent and a different haemoglobin gene (such as haemoglobin C (HbSC genotype) or a beta thalassaemia gene
(HbSβ+ or HbSβºthal genotype)) from the second parent.
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In people with SCD the abnormal sickle haemoglobin forms long polymers (chains) within the red blood cells when they become
de-oxygenated. This damages the red blood cells and makes them stickier, leading to blockages and reduced blood flow, causing pain
and organ damage. Fetal haemoglobin stops these polymers forming in the sickle haemoglobin within the red blood cell. The drug
hydroxyurea is used to raise fetal haemoglobin and can reduce the effects of the disease. This is an update of a previously published
Cochrane Review.
Search date
The evidence is current to 16 January 2017.
Study characteristics
We included eight studies (899 adults and children with SCD (HbSS, HbSC or HbSβºthal genotypes)). Studies lasted from six to 30
months.
Key results and quality of the evidence
In four studies, 577 adults and children with SCD were randomly selected to receive hydroxyurea or placebo. In two studies, 254
children with SCD, who were also at an increased risk of having a first or second stroke, were randomly selected to receive hydroxyurea
and phlebotomy (collection of blood) or blood transfusion and chelation (administration of agents to remove excess iron from the
body). These six studies only recruited people with HbSS or HbSβºthal genotypes so results do not apply to people with the HbSC
genotype.
There was moderate quality evidence from these six studies that those receiving hydroxyurea experienced significant reductions in
the frequency of pain crises, increases in fetal haemoglobin and decreases in neutrophil (white blood cell) counts compared to the
comparator treatment. There was no difference between people receiving hydroxyurea or other treatments in terms of quality of life,
deaths during the studies and side effects (including serious and life-threatening side effects); however, there is less information about
these outcomes in the studies, so the quality of this evidence is low.
Two further studies were included in the review. In one study, 22 children with SCD, who were also at an increased risk of having a
stroke, were randomly selected to receive hydroxyurea or no treatment (observation only) and in one study 44 adults and children were
randomly selected to receive treatments with or without adding hydroxyurea. Both studies showed an increase in fetal haemoglobin
for people receiving hydroxyurea compared to the comparator treatment and there were no deaths during the studies. There was no
difference between people receiving hydroxyurea or other treatments in terms of pain crises and side effects (including serious or life-
threatening side effects) and these studies did not measure quality of life. The quality of the evidence from these studies is very low,
given the studies were very small and only recruited around 20% of the intended number of people and results do not apply to all
people with SCD (different genotypes).
Conclusions
The evidence shows that hydroxyurea is likely to be effective in the short term at decreasing the frequency of painful episodes and
raising fetal haemoglobin levels in the blood in people with SCD. Hydroxyurea is also likely to be effective in preventing first strokes
for those at an increased risk of stroke and does not seem to be associated with an increase in any side effects (including serious and
life-threatening side effects).
There is currently not much evidence on whether hydroxyurea is beneficial over a long period of time, what the best dose to take is, or
whether treatment causes any long-term or serious side effects. More studies are needed to answer these questions.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hydroxyurea compared with placebo for sickle cell disease
Patient or population: adults and children with sickle cell disease
Settings: outpat ients
Intervention: hydroxyurea
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Hydroxyurea
Pain alteration1
Follow-up: 6 - 24
months
See comment See comment NA 577
(4 studies)2
⊕⊕⊕©
moderate5
All studies showed a
signif icant advantage
to hydroxyurea com-
pared to placebo (dif -
ferent measures of pain
alterat ion presented)1.
Life- threatening
illness
Follow-up: 6 - 24
months
See comment See comment NA 552
(3 studies)
⊕⊕⊕©
moderate5
Signif icant ly fewer oc-
currences of ACS (2
studies) and transfu-
sions (3 studies) on
hydroxyurea compared
to placebo. No sig-
nif icant dif f erences in
terms of stroke, hep-
at ic or splenic seques-
trat ion (two studies)
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Death during the study
(all deaths)
Follow-up: 6 - 24
months
26 per 1000 10 per 1000
(0 to 51 per 1000)
RR 0.39 (0.08 to 1.96) 577
(4 studies)2
⊕⊕⊕©
moderate5
There was also no sig-
nif icant dif f erence be-
tween groups in terms
of deaths related to
SCD
M easures of HbF (%)
Follow-up: 6 - 24
months
See comment See comment NA 577
(4 studies)2
⊕⊕⊕©
moderate5
There was a signif i-
cant increase in HbF
(%) in the hydroxyurea
group compared to the
placebo group in all
studies (dif f erent mea-
sures presented)3.
M easures of ANC
Follow-up: 6 - 24
months
See comment See comment NA 517
(3 studies)2
⊕⊕⊕©
moderate5
There was a sig-
nif icant decrease in
ANC in the hydroxyurea
group compared to the
placebo group in all
studies (dif f erent mea-
sures presented)3.
Quality of life: ’Health
Status Survey’ the ’Pro-
f ile of Mood States’ and
the ’Ladder of Life’
Follow-up: 24 months
See comment See comment NA up to 277
(1 study)
⊕⊕©©
low5,6
No signif icant dif f er-
ence in terms of any do-
main of any scale ex-
cept for pain recall at 18
months (MD 0.70, 95%
CI 0.11 to 1.29, P = 0.
02)4.
Adverse events or tox-
icity: dif f erences in
rates of specif ic ad-
verse events
Follow-up: 6 - 24
months
See comment See comment NA 577
(4 studies)2
⊕⊕©©
low5,7
Signif -
icant ly fewer events of
dactylit is and gastroen-
terit is on hydroxyurea
compared to placebo
No signif icant dif f er-
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ences between groups
in terms of all other
events
The basis for the assumed risk is the event rate in the control group unless otherwise stated in the comments and footnotes. The corresponding risk (and its 95% conf idence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ACS: acute chest syndrome; ANC: absolute neutrophil counts; CI: conf idence interval; HbF: f etal haemoglobin; M D: mean dif ference;NA: not applicable; RR: risk rat io; SCD:
sickle cell disease.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Pain alterat ion measured by mean annual pain crisis rate, t ime to init iat ion of treatment to f irst , second or third crisis,
number of vaso-occlusive crises, proport ion of part icipants experiencing pain, proport ion of hospitalisat ion for painful
episodes.
2. One study of 25 part icipants is of a cross-over design (Belgian Study 1996). Part icipants are counted only once in this
total.
3. Dif ferent measures presented - change f rom baseline or post intervent ion measures - therefore, data f rom all studies
could not be pooled.
4. Within the study (MSH 1995, reported in Ballas 2006), to allow for mult iple stat ist ical test ing of the quality of lif e
domains, a P value < 0.01 was considered signif icant. Therefore this result not interpreted as signif icant in the study
publicat ion.
5. Downgraded once due to applicability: only individuals with HbSS or HbSβº -thalassemia genotypes were included
therefore results are not applicable to individuals with HbSC genotype.
6. Downgraded once due to imprecision/ uncertainty: caut ion is encouraged regarding the interpretat ion of these results as
not all part icipants contributed data to all quality of lif e domains and the study publicat ion def ines stat ist ical signif icance
dif ferent ly to this review.
7. Downgraded once due to imprecision/ uncertainty: caut ion is encouraged regarding the interpretat ion of these results
due to the number of separate outcomes considered in analysis and the increased probability of a stat ist ical type I error.
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B A C K G R O U N D
Description of the condition
Haemoglobinopathies, including sickle cell disease (SCD), are
among the most common inherited disorders in the world. SCD
affects people originating from sub-Saharan Africa, Arab coun-
tries, the Mediterranean, the Indian subcontinent, the Caribbean
and South America, as well as African-Americans and descendants
from immigrants from the above countries in other parts of the
world. The genetic mutation gives carriers some advantage against
malaria and for this reason has persisted. There is an estimated
global birth rate of around 300,000 affected individuals per year,
the majority of which are in Africa (Piel 2013). There are an es-
timated 90,000 to 100,000 individuals with SCD in the USA
and approximately 12,000 to 15,000 in the UK (Brousseau 2010;
Hassell 2010; NICE 2012).
Haemoglobin is responsible for transporting oxygen around the
body packaged in red blood cells. SCD is caused by the recessive
inheritance of abnormal haemoglobins. People who inherit only
one sickle gene and the normal gene for adult haemoglobin (HbA)
are sickle cell carriers (sickle cell trait or AS) and are healthy.When
people are homozygous, because they have inherited two sickle
genes (SS), they have sickle cell anaemia, which is a variable clinical
condition, with the vast majority of individuals suffering some
pain attacks and a reduced life expectancy. Clinically significant
SCD also arises when people inherit the sickle gene from one
parent and another variant haemoglobin gene from the second
parent such as haemoglobin C (SC) or a beta thalassaemia gene
(Sβ+ or Sβ0). Sickle haemoglobin, when not carrying oxygen,
polymerises distorting the red blood cell into the classic ’sickle’
shape. The clinical problems arise predominantly as a result of
chronic anaemia and the blockage of small blood vessels, which
stops oxygen delivery to the tissues causing pain or organ damage
or both.
The most frequent clinical problem is pain which causes over 90%
of acute hospital admissions (Brozovic 1987) and significant mor-
bidity in the community (Fuggle 1996). Other acute complica-
tions include acute chest syndrome, stroke, splenic sequestration,
priapism and an increased risk of infection. SCD is a multi-organ
disease with a high chronic disease burden which increases with
increasing age. The majority of individuals are anaemic with hae-
moglobin levels of 60 to 90g/L in HbSS. Common chronic com-
plications include chronic sickle lung damage, pulmonary hyper-
tension, renal dysfunction, chronic bony damage (avascular necro-
sis), retinopathy and leg ulceration (Howard 2015).
Whilst the majority of those affected used to die in childhood, and
still do within parts of the developing world (Chakravorty 2015;
Grosse 2011), death rates in children in higher-income countries
have fallen over the past decades and themajority of children (over
95%) now survive to adulthood (Quinn 2010; Telfer 2007; van
der Plas 2011). Data from the USA reviewing national mortality
data from 1979 to 2005 has confirmed this decrease in mortality
in children, but showed an increased mortality rate in adults with
a median age of death of 42 years for women and 38 years for men
(Lanzkron 2013). Earlier data from the USA showed a median
survival for adults withHbSS in theUSA of 42 years inmen and 46
years in women and inHbSC of 60 years and 68 years, respectively
(Platt 1994). This contrasts with Jamaican figures which show
median survival for HbSS of 53 years for men and 58.5 years for
women (Wierenga 2001) and recent single-centre data from the
UK has shown median survival of 67 years in people with HbSS
and higher in those with HbSC (Gardner 2016). Data from the
USAhas also shownan increase in deaths following transition from
paediatric to adult services (Quinn 2010).Death is generally SCD-
related and is caused either by chronic organ failure consequent
to the sickling process (e.g. renal failure, pulmonary hypertension,
hepatic failure) (Manci 2003) or as a result of an acute catastrophic
event, such as stroke (Powars 1983), acute sickle chest syndrome,
splenic sequestration (Rogers 1978), sepsis (Manci 2003; van
der Plas 2011) or other complications (Gray 1991; Lanzkron
2013; Perronne 2002). The UK National Confidential Enquiry
into Patient Outcome and Death (NCEPOD) report reviewed
UK mortality data over 48 months and found six paediatric and
40 adult deaths. One paediatric death was due to pneumococcal
sepsis and two were due to sub-arachnoid haemorrhage. In adults
the main causes of death were stroke, multi-organ failure, acute
chest syndrome, renal failure and non-sickle causes (NCEPOD
2008).
Improvements in paediatric outcomes are related to the introduc-
tion of neonatal screening, early enrolment in comprehensive pae-
diatric care, penicillin prophylaxis, vaccination to decrease life-
threatening infection and primary stroke prevention with tran-
scranial Doppler screening. In adults, treatment has relied on the
avoidance of factors that precipitate crisis (including dehydra-
tion, infection and cold), and symptomatic treatment of the acute
painful episodes (Davies 1997a; Davies 1997b; Steinberg 1999;
STOP 2006). Hydroxyurea is currently the only licensed treat-
ment for SCD. Blood transfusion is often required and may be
used to treat acute complications or in the long term to treat or
prevent disease complications. Haemopoeitic stem cell transplan-
tation is the only currently available curative treatment option
and is offered to children with severe disease phenotype and an
human leukocyte antigen (HLA)-matched sibling donor. Other
donor transplant options and adult transplant are currently only
available in the context of clinical trials. Gene therapy offers an-
other potential curative treatment and is currently being investi-
gated in clinical trials.
Description of the intervention
Hydroxyurea (also known as hydroxycarbamide) is an anti-neo-
plastic oral drug and an inhibitor of ribonucleotide reductase
(BABYHUG 2011). The drug has been shown to have many ben-
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eficial effects for treating SCD; including increasing fetal haemo-
globin (HbF) concentration in red blood cells, improving nitric
oxide metabolism, reducing red cell-endothelial interaction and
erythrocyte density (Ware 2010). Such disease-modifying effects
have been shown to decrease episodes of pain, acute chest syn-
drome, hospital admissions and the need for transfusions among
people with SCD (MSH 1995; Strouse 2008); however, frequent
monitoring of the person’s blood count is required, in addition
to monitoring of toxicity. There are recognised, but mostly re-
versible, side effects of hydroxyurea, such as low neutrophil count,
low platelet count, anaemia, rash, headache and occasionally nau-
sea. Furthermore, it may have teratogenic effects and may have an
effect on male fertility (Strouse 2008; Zimmerman 2004). Long-
term or serious adverse effects (or both) of hydroxyurea are rare
(Steinberg 2010; Strouse 2008) and observational data suggest a
survival advantage for those treated with hydroxyurea (Steinberg
2010; Voskaridou 2010).
How the intervention might work
It has long been recognised that raised HbF levels can ameliorate
the clinical effects of SCD (Perrine 1978; Platt 1994). HbF lev-
els are high at birth and decrease over the first year of life and
and hence clinical manifestations are often delayed until the HbF
levels decrease. In addition, individuals who inherit high levels of
HbF display a milder disease phenotype. This is because the HbF
interferes with the polymer formation of the sickle haemoglobin
within the red blood cell. This polymerisation is the underlying
pathology in SCD. The more HbF there is, the greater the inhi-
bition. Hydroxyurea was first shown to raise HbF levels in SCD
in the 1980s (Platt 1984; Veith 1985). Its intermittent toxicity
on the bone marrow leads to a stress response and enhanced ery-
thropoiesis and levels of HbF. In addition to its effects on SCD
via HbF enhancement, hydroxyurea also improves blood flow and
reduces vaso-occlusion via other mechanisms including decrease
of adhesion molecules and stimulation of nitric oxide production
(Green 2014).
Why it is important to do this review
It is important to examine as a whole, the body of work relating to
the use of hydroxyurea in SCD, to evaluate the drug’s effectiveness
and tolerability in adults and children, and in the different types
of SCD, the dosage regimens and whether the setting appears to
influence the outcome, i.e. high-income versus low- and middle-
income countries. We aim to review any evidence relating to the
impact of hydroxyurea on the natural history of SCD and life
expectancy.
O B J E C T I V E S
The aims of this review are to determine whether the use of hy-
droxyurea in people with SCD:
1. alters the pattern of acute events, including pain;
2. prevents, delays or reverses organ dysfunction;
3. alters mortality and quality of life;
4. is associated with adverse effects.
In addition we hoped to assess whether the response to hydrox-
yurea in SCD varies with type of SCD, age of the individual, du-
ration and dose of treatment and healthcare setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised or quasi-randomised studies, irrespective of lan-
guage. Studies with quasi-randomised methods, such as alterna-
tion, were included if there was sufficient evidence that the treat-
ment and control groups were similar at baseline.
Types of participants
This review is limited to studies of hydroxyurea in SCD only. In
order to fully quantify the potential harm and toxicity of this drug,
a further review may need to be undertaken in all patient groups
treated with hydroxyurea.
People of any age with SCD (SS, Sβ , SC, Sβ+) proven by elec-
trophoresis and sickle solubility test, with family studies or DNA
tests as appropriate.
Types of interventions
Hydroxyurea in any formulation at all doses, compared to either
placebo or standard treatment (no placebo) for periods of one
month or longer.
Types of outcome measures
Primary outcomes
1. Pain alteration
i) frequency, duration, severity measured on self-
reported patient scales
ii) health service utilisation (e.g. inpatient days,
outpatient or accident and emergency department visits)
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iii) opioid use
2. Life-threatening illness (e.g. acute chest syndrome, stroke
and acute splenic sequestration)*
3. Death during the study
* In the 2017 update of the review, serious adverse events reported
in included studies (whether treatment-related or not) were in-
cluded under the definition of ’Life-threatening illness’.
Secondary outcomes
1. Measures of fetal haemoglobin (HbF or F cells) and
neutrophil counts
2. Other surrogate markers of response (e.g. haemoglobin,
mean cell volume, platelet count and growth)
3. Quality of life, time loss to school or employment,
integration into society, scales recording feeling of well-being and
global function (e.g. Karnofsky)
4. Measures of organ damage (e.g. spleen (pitted red cells),
chronic sickle lung disease (transfer factor), liver, chronic renal
failure (creatinine), priapism, leg ulcer, neurological damage (e.g.
intelligence quotient (IQ)))
5. Any reported adverse effects or toxicity
Search methods for identification of studies
We searched for all relevant published and unpublished trials with-
out restrictions on language, year or publication status.
Electronic searches
Relevant studies were identified from theCochrane Cystic Fibrosis
and Genetic Disorders Group’s Haemoglobinopathies Trials Reg-
ister using the terms: sickle cell AND hydroxyurea.
The Haemoglobinopathies Trials Register is compiled from elec-
tronic searches of the Cochrane Central Register of Controlled
Trials (Clinical Trials) (updated each new issue of the Cochrane
Library) and weekly searches of MEDLINE. Unpublished work
is identified by searching the abstract books of five major con-
ferences: the European Haematology Association conference; the
American Society of Hematology conference; the British Society
forHaematology Annual ScientificMeeting; theCaribbean Public
HealthAgencyAnnual ScientificMeeting (formerly theCaribbean
Health Research Council Meeting); and the National Sickle Cell
Disease Program Annual Meeting. For full details of all search-
ing activities for the register, please see the relevant section of the
Cochrane Cystic Fibrosis and Genetic Disorders Group’s website.
Date of the most recent search of the Group’s
Haemoglobinopathies Trials Register: 16 January 2017.
We also searched the following trials registries on 20 March 2017.
ClinicalTrials.gov using the following search terms: hydroxyurea
AND sickle.
WHO International Clinical Trials Registry Platform (ICTRP)
using the following search terms: hydroxyurea AND sickle.
Searching other resources
The bibliographic references of all retrieved studies and reviews
were assessed for additional reports of studies.
Data collection and analysis
Selection of studies
For the initial review, two authors (SCD and AO) independently
applied inclusion criteria. For the updates to this review, two au-
thors (AJ and SJN) performed this task. There were no discrepan-
cies between the authors’ assessments.
Data extraction and management
For the initial review, two authors (SCD and AO) independently
extracted the data. For the updates of the review, two authors
(AJ and SJN) performed this task. There were no discrepancies
between the authors’ assessments.
We intended to group outcome data into those measured at three,
six, twelve months and annually thereafter. When outcome data
were recorded at other time periods, then consideration was given
to examining these as well.
Assessment of risk of bias in included studies
For the initial review, two authors (SCD and AO) indepen-
dently assessed the methodological quality of each trial using the
Cochrane Risk of Bias tool (Higgins 2011). For the updates of
the review, two authors (AJ and SJN) performed these tasks. The
authors assessed methodological quality on the methods of con-
cealment and generation of randomisation sequence, blinding,
whether data were available to analyse on intention-to-treat ba-
sis and whether all randomised participants were included in the
analysis. There were no discrepancies between the authors’ assess-
ments.
Measures of treatment effect
For binary outcomes, we aimed to calculate a pooled estimate of
the treatment effect for each outcome across studies, (the risk of
an outcome among treatment allocated participants to the corre-
sponding risk among controls). For each study, we calculated risk
ratios (RR) with 95% confidence intervals (CI) for all important,
dichotomous outcomes. We present RR in preference to odds ra-
tios (OR), as OR give an inflated impression of the size of effect
where event rates are high, as is the case of these studies. For the
continuous outcomes, we aimed to calculate a pooled estimate of
treatment effect, using the mean difference (MD).
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Unit of analysis issues
One study was cross-over in design (Belgian Study 1996). We
planned to analyse data from this study using the approach recom-
mended by Elbourne (Elbourne 2002); extracting and analysing
data from paired analyses if possible.
Outcomes were measured at different time points throughout the
course of the MSH study. Methods to analyse aggregate longitu-
dinal data if individual patient data are not available are discussed
by Jones (Jones 2009); however, data presented did not allow the
use of these methods therefore we have carried out analysis at each
individual time point reported.
Dealing with missing data
In order to allow an intention-to-treat analysis, we collected data
by allocated treatment groups, irrespective of compliance, later
exclusion (regardless of cause) or loss to follow-up.
Assessment of heterogeneity
We assessed clinical heterogeneity by reviewing the differences
across trials in the characteristics of recruited participants and
treatment protocols. We assessed statistical heterogeneity using a
Chi² test for heterogeneity. We assessed heterogeneity using the
Q test (P < 0.10 for significance) and the I² statistic (greater than
50% indicating considerable heterogeneity (Higgins 2003)) and
visually by inspecting forest plots.
Data synthesis
We analysed data using the fixed-effect model, if we had found
considerable heterogeneity (I² statistic > 50%) thenwe would have
examined it using a random-effects model and subgroup analyses.
Subgroup analysis and investigation of heterogeneity
We intended to perform subgroup analyses according to age (in-
fant, child, adult etc), type of SCD (SS, Sβ , SC, Sβ+), dosage
regimen (study specific) and setting (community, hospital, outpa-
tient, etc), however, available data did not allow for these analyses.
Sensitivity analysis
We planned a sensitivity analysis based on the methodological
quality of the studies, including and excluding quasi-randomised
studies. However, no quasi-randomised studies were included in
the review, therefore, no sensitivity analyses were performed.
Summary of findings and quality of the evidence
(GRADE)
In a post hoc change from the protocol, we have presented four
summary of findings tables, one for each comparison of the review
(Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; Summary of findings 4).
1. Hydroxyurea compared to placebo for participants with
SCD
2. Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
3. Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
4. Hydroxyurea compared to no hydroxyurea for participants
with SCD
The following outcomes were reported in all tables (chosen based
on relevance to clinicians and consumers): pain alteration; life-
threatening illnesses; deaths during the study; measures of fetal
haemoglobin (HbF or F cells) and neutrophil counts, quality of
life and adverse events or toxicity.
We determined the quality of the evidence using the GRADE
approach; and downgraded evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results,
high probability of publication bias. We downgraded evidence by
one level if we considered the limitation to be serious and by two
levels if very serious.
For clarity in the tables, where outcomes were presented using
different measures (e.g. pain alteration) or different domains (e.g.
quality of life or adverse events), a general statement is made in the
table regarding the summary of findings for these outcomes and
the evidence is graded based on all of the measures or sub domains
combined.
R E S U L T S
Description of studies
Results of the search
See Figure 1 for PRISMA study flow diagram.
10Hydroxyurea (hydroxycarbamide) for sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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The previous versions of the review (Jones 2001, latest search
conducted May 2010) included two studies reported in 44 refer-
ences (Belgian Study 1996; MSH 1995); additionally, one ongo-
ing study (23 references) was identified (now completed) (BABY
HUG2011). Furthermore, two studies (two references) were listed
as awaiting classification (CHAMPS 2011; Jain 2012).
Searches conducted between June 2010 and January 2017 iden-
tified 74 records, seven of which were duplicates. Following re-
moval of these, 67 records were screened and five clearly irrelevant
records were excluded based on title and abstract. The remaining
62 records were further screened, full texts were accessed where
possible. A total of 29 records were linked to studies previously
identified (BABY HUG 2011; Belgian Study 1996; CHAMPS
2011; Jain 2012; MSH 1995), nine studies (reported in 10 ref-
erences) were excluded (see Excluded studies for further details),
three studies (reported in three references) were listed as ’awaiting
classification’ due to uncertainties around the study design and
population (see Characteristics of studies awaiting classification
for further details) and one study (reported in one reference) was
listed as ’ongoing’ (see Characteristics of ongoing studies for fur-
ther details).
The remaining 19 references corresponded to three new studies
which were eligible for inclusion (SCATE 2015; SWiTCH 2012;
TWiTCH 2016) and one reference previously excluded from the
previous version of the review (Ware 2006) was re-assessed and
included under the SWiTCH study (SWiTCH 2012). The three
studies previously identified as ongoing or awaiting classification
are now also eligible for inclusion in the review (BABY HUG
2011; CHAMPS 2011; Jain 2012)
In total, eight studies (reported in 118 references) are included in
the review (BABY HUG 2011; Belgian Study 1996; CHAMPS
2011; Jain 2012; MSH 1995; SCATE 2015; SWiTCH 2012;
TWiTCH 2016).
Included studies
Eight studies are included, with a total of 899 children and adults
(BABY HUG 2011; Belgian Study 1996; CHAMPS 2011; Jain
2012; MSH 1995; SCATE 2015; SWiTCH 2012; TWiTCH
2016)
The BABYHUG study was a multicentre, randomised, controlled
study conducted in 13 centres in the USA (BABY HUG 2011). It
was conducted in children aged nine months to 18 months who
had haemoglobin SS (HbSS) or haemoglobin Sβºthalassaemia
(HbSβºthal). Participants received liquid hydroxyurea (20 mg/kg
per day) or matching placebo for two years administered as an
oral syrup. A total of 193 children were randomised, 96 were ran-
domised to the hydroxyurea group and 97 were randomised to the
placebo group. Participants, caregivers and medical coordinating
centre staff were masked to treatment allocation and an unmasked
“primary end-point person” monitored laboratory values and as-
sisted in clinical management.
The Belgian Study was conduced in a single centre in Belgium
(Belgian Study 1996). This involved 25 children and young adults
with HbSS genotype with the aim of reviewing the impact on pain
events, hospitalisation and also on fetal haemoglobin reactivation.
This study was also placebo-controlled, randomised and blinded
to the participant but not to the caring physician. In addition,
this was a cross-over study which started at 20 mg/kg per day and,
unless cytopenia developed this was raised to a maximum of 25
mg/kg per day. In this study the participants were randomised to
either hydroxyurea or placebo for the initial six months and then
crossed over to the other arm. There was no statistically significant
period or carry-over effect present for the outcomes of the number
of hospitalisations and the number of days in hospital (period and
carry-over effects assessed by the Wilcoxon Rank Sum test).
The CHAMPS study was a randomised multicentre, phase II,
double blind placebo-controlled study with a 2x2 factorial design
(CHAMPS 2011). Eligible participants were over the age of five
years with HbSC and at least one vaso-occlusive event in the previ-
ous 12months (but none in the four weeks prior to study entry). A
total of 44 participants were randomised equally across four treat-
ment groups for 44 weeks: hydroxyurea (20 mg/kg per day) and
magnesium (0.6 mmol/kg per day in two doses), hydroxyurea (20
mg/kg per day) and placebo, placebo and magnesium (0.6 mmol/
kg per day in two doses), placebo and placebo. The study was not
designed to measure efficacy and measured only laboratory mea-
sures.The study was terminated early due to low enrolment after
44 participants had been randomised (target 188).
The Jain study was a double blind (participants, personnel and
outcome assessors) randomised controlled study conducted in a
tertiary hospital in Nagpur City, India (Jain 2012). The study
was conducted in children with sickle cell anaemia (proportion
with each genotype not stated) between the ages of five and 18
years with three ormore blood transfusions or vaso-occlusive crises
requiring hospitalisation per year despite high HbF. A total of 60
participants were randomised; 30 to hydroxyurea (fixed dose 10
mg/mg per day) and 30 to a matched placebo for 18 months.
The MSH study was a multicentre North American randomised
and double-blind study, which compared hydroxyurea with
placebo over two years in adults with sickle cell anemia (SS geno-
type only) with the objective of reducing the frequency pain crises
(MSH 1995). A total of 299 participants were randomised; 152
to hydroxyurea and 147 to matching placebo. Hydroxyurea was
started at low dose (15 mg/kg per day) and increased at 12-
weekly intervals by 5 mg/kg per day until mild bone marrow
depression, as judged by either neutropenia or thrombocytope-
nia, at that point the treatment was stopped (as reported for the
MSH study) (Handy 1996). Once the blood count had recovered,
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treatment was restarted at 2.5 mg/kg per day less than the toxic
dose. The study was therefore aiming for the maximum tolerated
dose (MTD) for each individual within the study. The study was
blinded and the study centre recorded and held the mean corpus-
cular volume (MCV) and HbF levels, which were not looked at
by the caring physicians as the MCV and HbF levels rise in most
people with SS taking hydroxyurea. As a result of the beneficial
effects observed in terms of the primary pain outcome, as reported
for the MSH study (Barton 1996), the study was stopped by the
National Heart, Lung and Blood Institute of the USA at a mean
follow-up of 21 months, before the planned 24 months of treat-
ment had been completed for all participants (MSH 1995). Long-
term follow-up continued for the study sample, with all partici-
pants offered treatment with hydroxyurea.
The SCATE (Sparing Conversion to Abnormal transcranial
doppler (TCD) Elevation) study was a Phase III multicentre, ran-
domised, controlled study conducted in three centres in the USA,
Jamaica and Brazil (SCATE 2015). The study was conducted in
children with sickle cell anemia (SS, Sβº, HbSOArab , HbSD),
haemoglobin SS (HbSS) or haemoglobin Sβº thalassaemia and
conditional TCD ultrasound velocities (170 cm to 199 cm per
second). A total of 22 participants were randomised; 11 to hydrox-
yurea at 20 mg/kg with escalation to maximum dose of 35 mg/
kg and 11 to standard treatment (observation). The primary aim
of the study was to establish whether treatment with hydroxyurea
could prevent conversion from conditional to abnormal time aver-
aged mean velocity (TAMV) and subsequent stroke in these chil-
dren. The planned length of follow-up was 30 months but the
study was terminated after 15 months of follow-up due to slow
participant accrual and the unlikelihood of meeting the trial re-
cruitment target (100) and the primary endpoint.
The SWiTCH study was a non-inferiority study, comparing hy-
droxyurea and phlebotomy to standard treatment (transfusion and
chelation) using a composite endpoint including secondary stroke
prevention and improved management of iron overload. It in-
cluded children with SCA (HbSS and HbSβºthal, HbSOArab)
and previous stroke, who had been receiving chronic transfusions
for at least 18 months (SWiTCH 2012). It was conducted in 26
sickle cell centres across the USA and a total of 134 children were
randomised (67 to the standard treatment and 67 to the hydrox-
yurea and phlebotomy group). Participants randomised to hydrox-
yurea and phlebotomy commenced hydroxyurea at 20 mg/kg with
escalation to MTD (defined by dose causing mild myelosuppres-
sion). Transfusion continued for four to nine months during hy-
droxyurea dose escalation. Once MTD was reached and transfu-
sion stopped, phlebotomy of 10 mL/kg monthly was performed,
if haemoglobin was sufficient.
The TWiTCH study was a multicentre phase III randomised
open label (partially masked) non-inferiority study conducted at
26 paediatric hospitals and health centres in the USA and Canada
(TWiTCH 2016). Eligible participants were children aged four
to 16 years with SCA (HbSS, HbSβºthal, HbSOArab) and ab-
normal TCD ultrasound velocities (≥ 200 cm per second) if they
had received 12 months of chronic transfusions. A total of 121
participants were randomised; 60 to hydroxyurea starting at 20
mg/kg per day escalated to the MTD compared to standard treat-
ment (transfusions) for 24 months. Children randomised to the
standard treatment group received their usual chelation therapy
or deferasirox to manage iron overload. Children randomised to
the hydroxyurea group continued to receive transfusions until hy-
droxyurea was escalated to the MTD and following the discon-
tinuation of transfusions, children received serial phlebotomy to
manage iron overload. The primary aim of the study was to estab-
lish whether treatment with hydroxyurea could prevent primary
stroke in these children. The study was terminated at the first in-
terim analysis when non-inferiority was demonstrated; the target
sample size had been recruited by this point.
Excluded studies
Following the 2010 search for the previous version of the re-
view (Jones 2001), four studies (reported in five references) were
excluded from the review (De Montalembert 2006; Silva-Pinto
2007; Voskaridou 2005;Ware 2006).However, as described above
(Results of the search), for the present version of the review, the
Ware reference was reassessed and included under the SWiTCH
study (SWiTCH 2012).
In total, 12 studies (14 references) were excluded from the cur-
rent review; five were not randomised (Al-Nood 2011; Pushi
2000; Silva-Pinto 2007; Silva-Pinto 2014; Voskaridou 2005),
four did not make a randomised comparison of hydroxyurea and
placebo or standard treatment (George 2013; NCT00004492;
NCT01960413; Vichinsky 2013), two were of one week of less
duration (De Montalembert 2006; NCT01848925) and one was
an inappropriate design for measuring the effectiveness of hydrox-
yurea (NCT02149537).
Risk of bias in included studies
See Figure 2 and Characteristics of included studies for more in-
formation.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
One study used an automated telephone response system to ran-
domise participants using lists that had been produced by the
medical co-ordinating centre (BABY HUG 2011). The SCATE
and TWiTCH studies used blocked randomisation and central
pharmacy allocation (SCATE 2015; TWiTCH 2016 ). All three
studies have been assessed as having a low risk of bias.
TheMSH study used computerised block randomisation, the Jain
trial used random number tables and the CHAMPS study used a
sequential allocation algorithm for randomisation (low risk of bias)
but none of these studies clearly stated any method of allocation
concealment (unclear risk of bias) (CHAMPS 2011; Jain 2012;
MSH 1995).
The Belgian study described the randomisation of participants as
“drawing sealed envelopes, patients were randomly allocated to
one of the following treatment sequences”, therefore, the gener-
ation and the allocation of the treatment sequence are not clear
from this statement (Belgian Study 1996). The hospital pharmacy
provided the treatment and placebo for each participant and both
were described as “indistinguishable.” The SWiTCH trial did not
discuss the method for randomisation or allocation concealment
and therefore this has been graded as unclear (SWiTCH 2012).
Blinding
The BABY HUG study was described as ’double blind’, the study
paper stated that “participants, caregivers and medical coordinat-
ing centre staff weremasked to treatment allocation” (BABY HUG
2011). The hydroxyurea and placebo powders were identical in
terms of appearance and packaging and the liquid formulations
had the same appearance and taste. In the Jain study, participants,
clinicians and outcome assessors including laboratory technicians
were blinded to treatment allocationwith placebo capsules of iden-
tical appearance (Jain 2012). These studies were assessed as low
risk of performance and detection bias.
In three studies, the blinding of participants and personnel was
also not possible due to the differences between the treatments
(hydroxyurea and standard treatment) (SCATE 2015; SWiTCH
2012; TWiTCH 2016). Outcome assessors were partially masked
in these studies for assessments around the primary outcomes re-
lated to neurological events such as stroke. Given the objective na-
ture of the primary outcomes of the studies judged by the blinded
outcome assessors, these studies were assessed as low risk of detec-
tion bias.
The MSH study was described as double blind (physician and
participant) (MSH 1995) and in the CHAMPS study, treatment
was assigned in combinations of identically appearing capsules
andblindingwas achieved by ’over-capsulating’ tablets (CHAMPS
2011). These two studies were assessed as low risk of performance
bias. The Belgian study was single-blinded (the participant was
unaware of the treatment schedule but the physician was aware
of the treatment schedule) because of the difficulty of blinding
the attending physician to the treatment received (Belgian Study
1996). It was not stated whether outcome assessors were blinded
in any of these three studies.
Incomplete outcome data
In four studies, the risk of bias was assessed as low since with-
drawals from treatment were documented, an intention-to-treat
analysis approach in primary analyses was used and all randomised
participants were included in the analysis (Jain 2012; MSH 1995;
SWiTCH 2012; TWiTCH 2016).
In the BABY HUG study, an intention-to-treat analysis was un-
dertaken for primary outcomes (via multiple imputation methods
to account for missing data) and for safety outcomes (BABYHUG
2011). Some of the secondary outcomes were reported for only
the individuals who completed the study or had data recorded for
specific measurements, but given that primary and important sa-
fety outcomes were reported using an intention-to-treat analysis,
this study was judged to be at a low risk of bias.
In the SCATE study, due to the early termination of the study, two
randomised participants did not receive their allocated treatment
(SCATE 2015). The primary analysis of this study used an in-
tention-to-treat approach and a sensitivity analysis considered the
actual treatment received so this study was also assessed as having
a low risk of bias.
In the Belgian study, three participants were excluded from the
analysis due to their failure to attend their monthly evaluation at
four to fivemonths (Belgian Study 1996). There was no discussion
ofwhether or not an intention-to-treat analysiswas used, therefore,
the risk of bias was judged to be unclear.
In the CHAMPS study, only participants who completed eight
weeks (primary outcome) or 44 weeks (secondary outcomes) of
follow-up were included in the results (CHAMPS 2011). This is
not an intention-to-treat approach so this trial was judged to be
at high risk of bias.
Selective reporting
Three studies defined outcomes in their methods sections, which
were reported in the results, and were thus assessed as having a
low risk of bias (BABY HUG 2011; Jain 2012; MSH 1995). The
CHAMPS studywas not designed tomeasure efficacy and reported
only laboratory-based outcomes; all of these outcomes were well-
defined in the methods and reported in the results, so this study
was assessed to be at a low risk of bias (CHAMPS 2011).
In the primary publication of the TWiTCH study, it was stated
the the secondary outcomes of neuropsychological status, quality
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of life and growth would be published at a later date (TWiTCH
2016). For the SWiTCH study, some outcomes (such as growth
and development, functional evaluations, neurocognitive evalua-
tions) do not yet seem to have been reported (SWiTCH 2012). As
we are not able to include the results at this time, we have judged
these studies to be at a high risk of selective reporting bias. If these
results can be included at a later date then this judgement will be
reconsidered (SWiTCH 2012; TWiTCH 2016). The final two
studies planned to measure outcomes which were not reported
due to difficulty in collecting the information to inform these out-
comes; these studies are also judged to be at a high risk of bias
(Belgian Study 1996; SCATE 2015).
Other potential sources of bias
One study was likely to be underpowered due to the early ter-
mination of the study with only 22% of the target sample size
recruited (SCATE 2015). Another study recruited only 23% of
the target sample size (CHAMPS 2011); however; this study was
not designed to measure efficacy and analyses were intended to
be exploratory, so we did not consider this study to be at high
risk of bias. Another study was also terminated early at the first
interim analysis, but the target sample size had been recruited at
this point so we did not consider this study to be at a high risk of
bias (TWiTCH 2016).
No other bias was identified for the remaining studies (BABY
HUG 2011; Belgian Study 1996; Jain 2012; MSH 1995;
SWiTCH 2012).
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings - Hydroxyurea compared with placebo for sickle
cell disease; Summary of findings 2 Summary of findings
- Hydroxyurea and phlebotomy compared to transfusion and
chelation for people with sickle cell disease and an increased
risk of stroke; Summary of findings 3 Summary of findings
- Hydroxyurea compared with observation for people with
sickle cell disease and an increased risk of stroke; Summary of
findings 4 Summary of findings - Hydroxyurea compared with
no hydroxyurea for people with sickle cell disease
For the 2017 update of the review six new studies were included
(BABY HUG 2011; Jain 2012; CHAMPS 2011; SCATE 2015;
SWiTCH 2012; TWiTCH 2016). Due to differences in the el-
igible populations and treatments in these new studies, we have
made the following comparisons.
1. Hydroxyurea compared to placebo for participants
with SCD
This comparison includes four studies (BABY HUG2011; Belgian
Study 1996; Jain 2012; MSH 1995).
2. Hydroxyurea and phlebotomy compared to
transfusion and chelation for participants with SCD
and an increased risk of stroke
This comparison includes two studies (SWiTCH 2012; TWiTCH
2016).
3. Hydroxyurea compared to observation for
participants with SCD and an increased risk of stroke
This comparison includes a single study (SCATE 2015).
4. Hydroxyurea compared to no hydroxyurea for
participants with SCD
This comparison includes a single study (CHAMPS 2011). We
note that this study recruits only individuals with HbSC; however,
this comparison (and other comparisons) are worded to allow for
future studies to be included in updates of this reviewwhich recruit
individuals of all genotypes to contribute to this comparison.
We have conductedmeta-analyses for comparisons 1 and 2 (above)
where appropriate and presented results narratively or in addi-
tional tables (Table 1; Table 2; Table 3; Table 4). Data are not
entered into analysis for the Belgian and CHAMPS studies due
to the presentation of results from cross-over and factorial de-
signs respectively; results are reported narratively (Belgian Study
1996; CHAMPS 2011). Long-term follow-up of the participants
inMSH study continued for up to 17 years andmany publications
presented results of long-term follow-up (see linked reference list
of theMSH study) (MSH 1995). After two years of double-blind,
placebo-controlled therapy, all participants were offered hydrox-
yurea therapy, so any results reported after the MSH study period
are uncontrolled. The long-term results are not therefore analysed
in this review.
Primary outcomes
1. Pain alteration
Hydroxyurea compared to placebo for participants with SCD
The MSH study defined pain crisis as a visit to a medical facil-
ity, lasting four or more hours, requiring opiate analgesia (MSH
1995). There was a statistically significant difference between the
hydroxyurea group and placebo group in the mean annual crisis
rate (all crises), MD -2.80 (95% CI -4.74 to -0.86) (P = 0.005)
and for crises requiring hospitalisation, MD -1.50 (95% CI -2.58
to -0.42) (P = 0.007) (Analysis 1.1).
TheMSH study also showed a reduction in median time (Kaplan-
Meier life table estimate) from the initiation of treatment to first
painful crisis (2.76months in the hydroxyurea arm compared with
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1.35 months on placebo (Cox regression P value = 0.014), second
painful crisis (6.58 months in the hydroxyurea group compared
with 4.13 months on placebo (Cox regression P value < 0.0024),
and third painful crisis (11.9 months in the hydroxyurea group
compared with 7.04 months on placebo (Cox regression P value
= 0.0002) (reported in Charache 1995). We note that the analy-
sis of time-to-first, second and third painful crisis seems to treat
crisis events independently which is unlikely to be a realistic as-
sumption. Furthermore, information relating to the analgesia used
by participants in this study has been reported, but has not been
presented according to the groups to which the participants were
randomised (reported in Ballas 1996).
The Jain study presented the number of clinical events (vaso-occlu-
sive crises) before and after intervention (Jain 2012).We could not
calculate change from baseline in the number of clinical events so
we have analysed between group data at 18 months and presented
the before and after data in an additional table (Table 1). After 18
months of treatment, there was a statistically significant difference
between the hydroxyurea group and placebo group, MD -9.60
(95% CI -10.86 to -8.34) (P < 0.00001) (Analysis 1.1).
The BABY HUG study showed a statistically significantly lower
proportion of participants experiencing pain in the hydroxyurea
group compared to the placebo group, RR 0.68 (95% CI 0.5 to
0.92) (BABY HUG 2011) (Analysis 1.2).
The Belgian study stated that “16 patients out of 22 (73%) did
not require any hospitalisation for painful episodes when treated
with hydroxyurea as compared with only 3 of 22 (14%) when
treated with placebo” (Belgian Study 1996). In addition, it showed
as reduction in mean hospital stay, with a stay of 5.3 days in the
hydroxyurea group and 15.2 days in the placebo group. A planned
outcome of ’number of days in pain’ was not reported in the trial
publication due to difficulties in collecting this information from
participants.
Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
Both studies reported the number of participants experiencing
’serious’ vaso-occlusive or sickle cell (SCA)-related pain events (
SWiTCH 2012; TWiTCH 2016) and one study also reported the
number of participants experiencing any vaso-occlusive or sickle
cell (SCA)-related pain event (SWiTCH 2012)
There was a statistically significantly higher proportion of partic-
ipants experiencing serious vaso-occlusive or sickle cell (SCA)-re-
lated pain in the hydroxyurea and phlebotomy group compared
to the transfusion and chelation groups in the SWiTCH and
TWiTCH studies, pooled RR 3.37 (95% CI 1.59 to 7.11) (P =
0.001) (SWiTCH 2012; TWiTCH 2016), but there was no sig-
nificant difference between the groups in terms of all SCA pain
events in the SWiTCH study, RR 1.03 (95% CI 0.81 to 1.30) (P
= 0.81) (SWiTCH 2012) (Analysis 2.1).
Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
No informationwas reported for this outcome in the SCATE study
(SCATE 2015).
Hydroxyurea compared to no hydroxyurea for participants
with SCD
No information was reported for this outcome in the CHAMPS
study (CHAMPS 2011).
2. Life-threatening illness
Hydroxyurea compared to placebo for participants with SCD
The BABY HUG and the MSH studies provided data on the oc-
currence of acute chest syndrome, stroke and participants trans-
fused (BABY HUG 2011; MSH 1995). Statistically significant
advantages in the hydroxyurea group was the reduction in the oc-
currence of the acute sickle chest syndrome, pooled RR 0.43 (95%
CI 0.29 to 0.63) (P < 0.0001), and also that fewer participants on
hydroxyurea underwent transfusions, pooled RR 0.66 (95% CI
0.52 to 0.82) (P = 0.0003). There was no statistically significant
difference in terms of stroke, pooled RR 0.54 (95% CI 0.12 to
2.53) (P = 0.44) (Analysis 1.3).
The MSH study reported data on hepatic sequestration and the
BABY HUG study reported data on splenic sequestration, the
differences between the groups were not statistically significant,
RR 0.32 (95% CI 0.03 to 3.06) (P = 0.32) and RR 0.90 (95% CI
0.36 to 2.23) (P = 0.82), respectively (MSH 1995; BABY HUG
2011) (Analysis 1.3).
The Jain study presented the number of clinical events (blood
transfusions and hospitalisations) before and after intervention
(Jain 2012).We could not calculate change frombaseline the num-
ber of clinical events so we have analysed between group data at 18
months and presented the before and after data in an additional
table (Table 1). After 18 months of treatment, there was a statis-
tically significant difference between the hydroxyurea group and
placebo group in the number of blood transfusions, MD -1.85
(95% CI -2.18 to -1.52) (P < 0.00001) and in the number of hos-
pitalisations, MD -8.89 (95% CI -10.04 to -7.74) (P < 0.00001).
The duration of hospitalisation was also significantly less in the
hydroxyurea group than the placebo group, MD -4.00 days (95%
CI -4.87 to -3.13) (P < 0.00001) (Analysis 1.4).
No informationwas reported for this outcome in the Belgian study
(Belgian Study 1996).
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Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
The primary aim of the TWiTCH study was to prevent primary
stroke; 29 neurologic events occurred during the study, 17 in the
hydroxyurea group and 12 in the standard treatment group; but
none were deemed to be stroke or cerebral infarcts (TWiTCH
2016). Three events in each group were deemed to be transient
ischaemic attacks and worsened vasculopathy developed in one
participant in the standard treatment group.
The aim of the SWiTCH study was to prevent secondary stroke;
91 new-neurologic events were assessed for stroke and seven partic-
ipants (all in the hydroxyurea treatment group) has positive stroke
adjudication, one of which was fatal (SWiTCH 2012). There were
also 20 transient ischaemic attack events in 15 participants (nine
on transfusion and chelation and six on hydroxyurea and phle-
botomy).
There was no statistically significant difference in life-threatening
neurological events between the treatment groups in either study
from the analysis conducted in this review (Analysis 2.2); however,
following the seven events in the hydroxyurea and phlebotomy
group, the SWiTCH study was terminated following an interim
analysis demonstrating the inability of the primary outcome to
reduce secondary stroke occurrence while managing iron overload
“within the non-inferiority stroke margin” (SWiTCH 2012).
The SWiTCH and TWiTCH studies reported serious adverse
events (including life-threatening events) and other adverse events
or toxicities separately (see Secondary outcomes for Adverse
events) (SWiTCH 2012; TWiTCH 2016). Thirty-eight partic-
ipants experienced 81 serious adverse events in the SWiTCH
study and 15 participants experienced 33 serious adverse events
in the TWiTCH study (SWiTCH 2012; TWiTCH 2016). There
were significantly more participants experiencing serious adverse
events and SCD-related adverse events in the hydroxyurea treat-
ment groups compared to the transfusions groups; pooledRR1.93
(95% CI 1.17 to 3.20) (P = 0.01) and RR 3.10 (95% CI 1.42 to
6.75) (P = 0.004), respectively (Analysis 2.2). There was no signif-
icant difference between groups in terms of hepatobiliary disease
and splenic sequestration but serious acute chest syndrome and
infections and infestations were significantly more common on
hydroxyurea and phlebotomy treatment than on transfusion and
chelation, pooled RR 2.84 (95% CI 1.25 to 6.42) (P = 0.01) and
pooled RR 3.65 (95% CI 1.05 to 12.76) (P = 0.04), respectively
(Analysis 2.2).
As the control arm of the two studies in this comparison involved
blood transfusions, we did not consider the number of participants
requiring blood transfusion to be a life-threatening event for this
comparison.
Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
The primary aim of the SCATE study was to prevent stroke and no
strokes or transient ischaemic attacks occurred during the study.
Vaso-occlusive events (pain and acute chest syndrome) occurred
more commonly in the observation arm than the hydroxyurea arm,
but this was not statistically significant (SCATE 2015). There was
also no statistically significant difference in cases of acute splenic
sequestration or the number of participants requiring blood trans-
fusion (Analysis 3.1).
Hydroxyurea compared to no hydroxyurea for participants
with SCD
No information was reported for this outcome in the CHAMPS
study (CHAMPS 2011).
3. Death during the study
Hydroxyurea compared to placebo for participants with SCD
TheMSH study reported death and causes of death (MSH 1995);
no deaths were reported to be related to hydroxyurea treatment.
There were two deaths in the treated group and five in the placebo
group including one homicide. There was no statistically signif-
icant difference between treatment and control groups for this
comparison (Analysis 1.5).
There were no deaths in the remaining three studies (BABY HUG
2011; Belgian Study 1996; Jain 2012).
Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
In the SWiTCH study, there was one death in the standard treat-
ment arm (pulmonary embolism) and one death in the hydrox-
yurea treatment arm (fatal haemorrhagic stroke) (SWiTCH 2012).
There were no deaths reported in the TWiTCH study (TWiTCH
2016). There was no statistically significant difference between
treatment and control groups for this comparison (Analysis 2.3).
Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
There were no deaths reported in the SCATE study (SCATE
2015).
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Hydroxyurea compared to no hydroxyurea for participants
with SCD
There were no deaths reported in the CHAMPS study (CHAMPS
2011).
Secondary outcomes
1. Measures of fetal haemoglobin and neutrophil counts
Hydroxyurea compared to placebo for participants with SCD
The BABYHUG study reported the change from baseline in HbF
(%) and absolute neutrophil count (ANC); there was a statistically
significant increase in HbF in the hydroxyurea group compared
to the placebo group, MD 6.70 (95% CI 4.75 to 8.65) (P <
0.00001) (BABY HUG 2011) (Analysis 1.6) and a statistically
significant decrease in ANC in the hydroxyurea group compared
to the placebo group, MD -1.70 (95% CI -2.90 to -0.50) (P <
0.00001) (Analysis 1.8).
The Jain andMSH studies presented results before and after inter-
vention (Jain 2012; MSH 1995). We could not calculate change
from baseline so we have analysed between group data at the end
of the study and presented the before and after data in additional
tables (Table 1; Table 2). After the intervention, there was a statis-
tically significant increase in HbF in the hydroxyurea group com-
pared to the placebo group in the two studies, pooled MD 4.07
(95% CI 2.95 to 5.18) (P < 0.0001) (Analysis 1.7).
The MSH study also reported the neutrophil response after treat-
ment; at 10 weeks and at two years there was a statistically sig-
nificant decrease in neutrophil response in the hydroxyurea group
compared to the placebo group, MD -1.90 (95% CI -2.51 to -
1.29) (P < 0.0001) and MD -1.50 (95% CI -2.01 to -0.99) (P <
0.0001), respectively (MSH 1995) (Analysis 1.9).
One study reported an increase in HbF and a decrease in ANC
after six months of hydroxyurea treatment, but did not make a
comparison to the placebo group (Belgian Study 1996).
Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
The SWiTCH study reported the change from baseline in HbF
(%) and ANC; there was a statistically significant difference be-
tween treatment groups for both of these measures (SWiTCH
2012). The results were presented as median and interquartile
ranges and therefore could not be entered into a meta-analysis; see
an additional table for a summary of these results (Table 3).
The TWiTCH study reported the change from baseline in HbF
(%) and ANC; there was a statistically significant increase in HbF
in the hydroxyurea group compared to the placebo group, MD
15.60 (95%CI 13.41 to 17.79) (P < 0.00001) (Analysis 2.4) and a
statistically significant decrease in ANC in the hydroxyurea group
compared to the placebo group, MD -4.40 (95% CI -5.44 to -
3.36) (P < 0.00001) (TWiTCH 2016) (Analysis 2.5).
Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
The SCATE study reported a significant increase in HbF and a
significant decrease in ANC at last follow-up in the hydroxyurea
group compared to observation (SCATE 2015). Results were re-
ported as median values so could not be included in analysis, see
an additional table for a summary of these results (Table 4).
Hydroxyurea compared to no hydroxyurea for participants
with SCD
The CHAMPS study, which included participants with HbSC
only, reported a statistically significant increase inHbF for hydrox-
yurea treatment compared to no hydroxyurea treatment at eight
weeks and 24 weeks but no statistically significant difference was
observed for ANC (CHAMPS 2011). Due to the presentation of
results from factorial design of the trial, results cannot be entered
into analysis.
2. Other surrogate markers of response
Hydroxyurea compared to placebo for participants with SCD
The BABY HUG study reported change from baseline in hae-
moglobin (Hb), mean cell volume (MCV), white blood count
(WBC), platelet count, absolute reticulocyte count (ARC), retic-
ulocytes and total bilirubin (BABY HUG 2011).
There was a statistically significant increase in Hb (Analysis 1.10),
MCV (Analysis 1.11) and a statistically significant decrease in
WBC(Analysis 1.12), ARC (Analysis 1.13), reticulocytes (Analysis
1.14) and total bilirubin (Analysis 1.15) in the hydroxyurea group
compared to the placebo group. There was no statistically signifi-
cant difference between groups in platelet count (Analysis 1.16).
The Jain andMSH studies presented results before and after inter-
vention (MSH 1995; Jain 2012). We could not calculate change
from baseline so we have analysed between-group data at the end
of the study and presented the before and after data in additional
tables (Table 1; Table 2). After the intervention comparing hy-
droxyurea and placebo groups, there was a statistically significant
increase in Hb andMCV at 10 weeks and at the end of the studies
(Analysis 1.17, Analysis 1.18), a statistically significant decrease in
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total bilirubin at the end of the studies (Analysis 1.19) reticulo-
cytes at 10 weeks, 18 months and two years (Analysis 1.20) and a
decrease in platelet count at 10 weeks, 18 months and two years
which was not statistically significant (Analysis 1.21).
In terms of other laboratory measures comparing hydroxyurea and
placebo groups at the end of the studies, there was a statistically sig-
nificant increase in packed cell volume (Analysis 1.22), F reticulo-
cytes (Analysis 1.23) and F cells (Analysis 1.24), a statistically sig-
nificant decrease in red blood count (Analysis 1.25), white blood
count (Analysis 1.26) and dense cells (Analysis 1.27) and no dif-
ference between groups in leucocytes (Analysis 1.28), creatinine
(Analysis 1.29), aspartate aminotransferase (Analysis 1.30) and al-
kaline phosphatase (Analysis 1.31).
One study reported differences in haematologic values after six
months of treatment such as Hb, MCV (both significantly in-
creased), platelet count and WBC (both significantly decreased)
but only in the hydroxyurea group without comparison to the
placebo group (Belgian Study 1996).
The BABY HUG study reported change from baseline in growth,
there were no significant differences between the groups in terms
of height, weight or head circumference (BABY HUG 2011) (
Analysis 1.32). TheMSH study reported on weight gain after two
years was reported in the MSH study as a mean rise of 3% in the
hydroxyurea treated group and 6% in the placebo group, which
was not statistically significant (MSH 1995).
Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
The SWiTCH study reported the change from baseline several
laboratory and haematologic measurements such as Hb, MCV,
WBC, platelet count and total bilirubin (SWiTCH 2012). There
was a statistically significant difference between treatment groups
for most of the measurements (increase in HbF, HbS, MCV and
decrease in ANC, HbA, WBC, ARC, platelets, serum ferritin and
LDH), except forHb and liver iron concentration; the results were
presented as median and interquartile ranges and therefore could
not be entered into a meta-analysis; see an additional table for
summary of these results (Table 3).
The TWiTCH study reported the change from baseline in Hb,
MCV, WBC, ARC, platelet count, total bilirubin, sickle haemo-
globin, liver iron concentration, serum ferritin and lactate dehy-
drogenase (TWiTCH 2016). There was a statistically significant
increase in MCV (Analysis 2.6) and sickle haemoglobin (Analysis
2.7) and a statistically significant decrease in Hb (Analysis 2.8),
ARC (Analysis 2.9), WBC (Analysis 2.10), platelets (Analysis
2.11), total bilirubin (Analysis 2.12), liver iron concentration
(Analysis 2.13), serum ferritin (Analysis 2.14) and lactate dehydro-
genase (Analysis 2.15) in the hydroxyurea and phlebotomy group
compared to the transfusion and chelation group,
Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
The SCATE study reported differences in haematologic values
and growth values at last follow-up (SCATE 2015). There was a
statistically significant increase in Hb and MCV in the hydrox-
yurea group compared to the observation group.Other values were
not statistically significantly different (differences the hydroxyurea
group and observation group in Hb and MCV were statistically
significant and other values were not significant (WBC, ANC,
Platelets, ARC, HbF, weight and height)). Results were reported
as median values so could not be included in analysis, see an ad-
ditional table for a summary of these results (Table 4).
Hydroxyurea compared to no hydroxyurea for participants
with SCD
The CHAMPS study reported statistically significant increases
in MCV and Hb and a statistically significant decrease in WBC
and platelets between hydroxyurea treatment and no hydroxyurea
treatment at eight weeks and 24 weeks (CHAMPS 2011). No sta-
tistically significant difference was observed in red blood cell count
(RBC), mean corpuscular haemoglobin concentration (MCHC)
and ARC. Due to the presentation of results from factorial design
of the study, results cannot be entered into analysis.
3. Quality of life
Hydroxyurea compared to placebo for participants with SCD
The MSH study has published in abstract limited quality of
life data collected at six-monthly intervals (MSH 1995, reported
in Terrin 1999 and Ballas 2006). Health-related quality of life
(HQoL) was measured using three measures from the ’Health Sta-
tus Survey’ (nine scales), the ’Profile of Mood States’ (four scales)
and the ’Ladder of Life’. A lower score for each measure equated
to a lower quality of life.
Changes frombaseline are presented for only threemeasures: Gen-
eral Health Perception,’ ’Social Function’ and ’Changes in Ladder
of Life’ and four week score was reported for ’Pain Recall’.
There was a statistically significant advantage to hydroxyurea com-
pared to placebo in terms of general health perception at 18
months MD 0.90 (95% CI 0.08, 1.72) (P = 0.03) (Analysis 1.33)
and pain recall at 18 months, MD 0.70 (95% CI 0.11 to 1.29) (P
= 0.02) (Analysis 1.34) but not at any other measured time point
for either measure.
There were no statistically significant differences between the hy-
droxyurea and placebo groups at six months, one year, 18 months
and two years for ’Social Function’ and ’Changes in Ladder of Life’
(Analysis 1.35, Analysis 1.36).
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For the MSH study, it was reported that there were no significant
differences between groups in other measures of HQoL (using
a P value cut-off for statistical significance of P < 0.01 to allow
for statistical testing of multiple HQoL domains) (MSH 1995
reported inBallas 2006). Results are presented as final scores rather
than change from baseline so are not entered into analysis in this
review. We encourage caution when interpreting results of these
quality of life scales as not all participants contributed data towards
these analyses.
No information was reported for this outcome in the remaining
three studies (BABYHUG 2011; Belgian Study 1996; Jain 2012).
Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
Quality of life was measured in the TWiTCH study, but results
have not yet been published; if results are published at a later date,
theywill be included in an update of this review (TWiTCH 2016).
No information was reported for this outcome in the remaining
study (SWiTCH 2012).
Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
Health-related quality of life was a planned outcome in the SCATE
study but was not reported due to difficulties in collecting in-
formation from participants at the early study termination date
(SCATE 2015).
Hydroxyurea compared to no hydroxyurea for participants
with SCD
This outcomewas not reported in theCHAMPS study (CHAMPS
2011).
4. Measure of chronic organ damage
Hydroxyurea compared to placebo for participants with SCD
The MSH study reported similar rates of new leg ulcers, RR 0.85
(95% CI 0.44 to 1.64) (P = 0.64) and avascular necrosis of femur
and humerus, RR 0.97 (95% CI 0.39 to 2.37) (P = 0.64), in
both groups (MSH 1995). The BABY HUG study reported more
participants with decreased spleen function at exit in the placebo
group than the hydroxyurea group but this was not statistically
significant, RR 0.72 (95% CI 0.44 to 1.16) ( P = 0.18) (BABY
HUG 2011) (Analysis 1.37).
The BABY HUG study reported several measures of:
• splenic function: diethylenetriaminepentaacetic acid
glomerular filtration rate (Analysis 1.38); Howell-Jolly body
(HJB) (Analysis 1.39); pitted cells (Analysis 1.40); spleen to liver
ratio of counts (Analysis 1.41); and spleen volume (Analysis
1.42);
• renal function: creatinine (Analysis 1.43); Schwartz
glomerular filtration rate (GFR) (Analysis 1.44); cystatin C
(Analysis 1.45); urine osmolality (Analysis 1.46); urine pH
(Analysis 1.47); urine-specific gravity (Analysis 1.48); and total
kidney volume (Analysis 1.49); and
• central nervous system function: TCD velocity (Analysis
1.50); Bayley mental developmental index (MDI) and Bayley
motor performance developmental index (PDI) (Analysis 1.51).
Several of the outcomes showed significantly fewer indications
of chronic organ damage on hydroxyurea compared to placebo
(Analysis 1.39; Analysis 1.40; Analysis 1.41; Analysis 1.43;
Analysis 1.46; Analysis 1.48, Analysis 1.49; Analysis 1.50); how-
ever, given the number of outcomes measured and the increased
probability of type I statistical error and spurious result, the statis-
tical significance of these secondary endpoint comparisons must
be carefully interpreted (BABY HUG 2011).
No information was reported for this outcome in the remaining
two studies (Belgian Study 1996; Jain 2012).
Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
The TWiTCH study reported a measure of central nervous sys-
tem function (TWiTCH 2016). Eligible participants had abnor-
mal TCD ultrasound velocities (> 200 cm per second). The final
TCD velocity was significantly lower in the hydroxyurea and phle-
botomy group compared to the transfusion and chelation group,
MD -5.00 (95% CI -9.16 to -0.84) (P = 0.02) (Analysis 2.16).
This outcome was not reported in the SWiTCH study (SWiTCH
2012).
Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
The aim of the SCATE study was to prevent conversion from
conditional to abnormal time averaged mean velocity (TAMV)
and subsequent stroke; one participant in the hydroxyurea group
and five participants in the observation group converted, this dif-
ference between groups was not statistically significant (Analysis
3.2) but there was a significantly lower TAMV in the hydroxyurea
group compared to the observation group, MD -25.70 (95% CI
-45.38 to -6.02) (P = 0.01) (SCATE 2015) (Analysis 3.3). No
strokes occurred during the study.
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Hydroxyurea compared to no hydroxyurea for participants
with SCD
This outcomewas not reported in theCHAMPS study (CHAMPS
2011).
5. Adverse effects or toxicity
As it is difficult to distinguish between adverse reactions (i.e. ad-
verse events which are definitely drug-related) and other adverse
events which may be sickle- or transfusion-related, we have re-
ported all adverse events (or adverse effects) as they are reported
in the study publications. Where possible, we have noted which
adverse effects are defined as drug-related, sickle-related or trans-
fusion-related from the study publications.
Hydroxyurea compared to placebo for participants with SCD
The possible adverse effects reported in the MSH study were hair
loss, skin rash, fever, gastro-intestinal disturbance, and ’other’ re-
ported events (MSH 1995). There was no statistically significant
difference between the groupswith thesemeasures (Analysis 1.52).
In the MSH study, toxicity relating to the blood count was de-
fined as less than 2500 x 10 neutrophils/L, less than 95,000 x
10 platelets/L, and haemoglobin concentration less than 5.3 g/
dL (MSH 1995). Using these definitions 120 of the hydroxyurea-
treated participants (79%) and 54 placebo participants (37%) be-
came ’toxic’ at least once, resulting in a dose modification. Impor-
tantly, no infections were related to neutropenia and no ’bleeding’
episode could be related to thrombocytopenia.
The BABY HUG study reported the proportion of participants
experiencing a range of adverse events such as dactylitis, priapism,
sepsis or bacteraemia, splenomegaly, ANC below 500, ANC 500
to 1250, thrombocytopaenia, severe anaemia, alanine transami-
nase over 150, bilirubin, creatinine, skin and subcutaneous disor-
ders and splenic sequestration (BABY HUG 2011). The rates of
these specific events were generally quite similar with only dactyli-
tis and gastroenteritis showing any differences between the two
treatment groups, with statistically significantly fewer events in the
hydroxyurea group (Analysis 1.52); however, given the number of
outcomes measured and the increased probability of type I statisti-
cal error and spurious group differences, the statistical significance
must be carefully interpreted.
Nomajor adverse events occurred in either group in the Jain study
(Jain 2012); three participants in the hydroxyurea group experi-
enced skin rash and two experienced nausea, but this was not a
statistically significant difference compared to the placebo group
(Analysis 1.52). No participants experienced alopecia, leucopenia,
neutropenia, renal or hepatic toxicity.
It was stated that two children developed transient mild throm-
bocytopenia in the Belgian study but the treatment allocation of
these children was not stated (Belgian Study 1996).
Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and an increased risk of
stroke
Life-threatening adverse events are presented above in primary
outcome 2 (Analysis 2.2).
In the TWiTCH study it was stated that adverse events were bal-
anced between the two groups, in the transfusion and chelation
group there were 287 sickle-related adverse events and 279 sickle-
related adverse events in the hydroxyurea and phlebotomy group
(TWiTCH 2016). There were 19 adverse events related to chela-
tion treatment in nine children in the control group (aminotrans-
ferases, gastrointestinal symptoms, increased serum creatinine, in-
creased serum bilirubin, rash) and 18 adverse events related to
phlebotomy in 14 children in the hydroxyurea treatment group
(details not stated). No events related to hydroxyurea were re-
ported. There was insufficient information to enter into the anal-
ysis, we hope to include any future information in an update.
In the SWiTCH study, there were a total of 1253 non-neurolog-
ical adverse events in 128 individuals, there was no statistically
significant difference between groups in the number of partici-
pants experiencing any adverse event, RR 0.99 (95% CI 0.92 to
1.05) (P = 0.66) (SWiTCH 2012) (Analysis 2.17). In terms of
specific events, there was no statistically significant difference be-
tween treatment arms for most events. There was a statistically
significant difference in terms of immune disorders (more in the
transfusion and chelation group), reticulocytopenia, neutropenia
and anaemia (more in the hydroxyurea and phlebotomy group)
(Analysis 2.17); however, given the number of outcomes measured
and the increased probability of type I statistical error and spuri-
ous group differences, the statistical significance must be carefully
interpreted.
Hydroxyurea compared to observation for participants with
SCD and an increased risk of stroke
Adverse events reported in the SCATE study included transient
neutropenia, reticulocytopenia, parasite infestation, headache and
dizziness (SCATE 2015). There was no significant difference be-
tween treatment arms for any adverse event (Analysis 3.4)
Hydroxyurea compared to no hydroxyurea for participants
with SCD
In the CHAMPS study, adverse events and toxicity were only re-
ported for all randomised participants and not by treatment group
(CHAMPS 2011). A total of 22 serious adverse events were ob-
served in 10 participants and 293 adverse events in 38 partici-
pants. It was reported that vaso-occlusive pain crises, headache
or migraine, upper respiratory infection, skin rash diarrhoea and
abdominal pain were the most common adverse events during
the trial and these events were evenly distributed across treatment
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groups. Two individuals, one receiving hydroxyurea and one not
receiving hydroxyurea experienced mild neutropenia.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Hydroxyurea and phlebotomy compared to transfusion and chelation for people with sickle cell disease and an increased risk of stroke
Patient or population: adults and children with sickle cell disease and an increased risk of stroke
Settings: outpat ients
Intervention: hydroxyurea and phlebotomy
Comparison: t ransfusion and chelat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Transfusion and chela-
tion
Hydroxyurea and phle-
botomy
Pain alteration: propor-
t ion experiencing seri-
ous VOC or sickle-re-
lated pain events
Follow-up: 24 to 30
months
213 per 1000 718 per 1000
(339 to 1000 per 1000)
RR 3.37 (95% CI 1.59 to
7.11)
254
(2 studies)
⊕⊕©©
low4,5
No signif icant dif f er-
ence between treat-
ment groups in terms
of all pain events (seri-
ous and non-serious) in
1 study (RR 1.03, 95%
CI 0.81 to 1.30)
Life- threatening
illness
Follow-up: 24 - 30
months
See comment See comment NA 254
(2 studies)
⊕⊕⊕©
moderate4
No signif icant dif f er-
ence between groups
in lif e-threatening neu-
rological events, hep-
atobiliary disease and
splenic sequestrat ion;
signif icant ly more ACS
and infect ions and in-
festat ions in the hy-
droxyurea and phle-
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botomy compared to
the transfusion and
chelat ion group
Death during the study
(all deaths)
Follow-up: 24 - 30
months
1 death occurred in the
transfusion and chela-
t ion group of 1 study1.
1 death occurred in
the hydroxyurea and
phlebotomy group of 1
study1.
RR 0.99 (95% CI 0.06 to
15.42)
254
(2 studies)
⊕⊕©©
low4,5
M easures of HbF (%)
Follow-up: 24 to 30
months
See comment See comment NA 254
(2 studies)
⊕⊕⊕©
moderate4
There was a signif i-
cant increase in HbF(%)
in the hydroxyurea and
phlebotomy group com-
pared to the transfusion
and chelat ion group for
both studies (dif f erent
measures presented)2.
M easures of ANC
Follow-up: 24 to 30
months
See comment See comment NA 254
(2 studies)
⊕⊕⊕©
moderate4
There was a signif i-
cant decrease in ANC
in the hydroxyurea and
phlebotomy group com-
pared to the transfusion
and chelat ion group for
both studies (dif f erent
measures presented)2.
Quality of life Outcome not reported3 NA
Adverse events or tox-
icity: dif f erences in
rates of specif ic ad-
verse events
See comment See comment NA 254
(2 studies)
⊕⊕©©
low4,6
There was a stat ist i-
cally signif icant dif f er-
ence in terms of im-
mune disorders (more
in transfusion and
chelat ion group), ret ic-
ulocytopenia, neutrope-
nia and anaemia (more
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in hydroxyurea and
phlebotomy group) in 1
study and the rate of
adverse events was bal-
anced across groups in
the other study
The basis for the assumed risk is the event rate in the control group unless otherwise stated in the comments and footnotes. The corresponding risk (and its 95% conf idence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ACS: acute chest syndrome; ANC: absolute neutrophil counts; CI: conf idence interval; HbF: f etal haemoglobin; NA: not applicable; RR: risk rat io; VOC: vaso-occlusive crisis.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Absolute data presented for number of deaths as the conf idence interval of the relat ive ef fect very large due to the small
number of events.
2. Dif ferent measures presented - mean or median change f rom baseline - therefore data f rom all studies could not be pooled.
3. Quality of lif e data was collected in TWiTCH 2016; to date, primary results of this study have been published but not quality
of lif e data. When available, quality of lif e data will be included in an update of this review.
4. Downgraded once due to applicability: only children with HbSS or HbSβº -thalassemia were included therefore results are
not applicable to adults or individuals with HbSC genotype.
5. Downgraded once due to imprecision: small number of events and large CI around the relat ive ef fect.
6. Downgraded once due to imprecision/ uncertainty: caut ion is encouraged regarding the interpretat ion of these results due
to the number of separate outcomes considered in analysis and the increased probability of a stat ist ical type I error.
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Hydroxyurea compared with observation for people with sickle cell disease and an increased risk of stroke
Patient or population: adults and children with sickle cell disease and an increased risk of stroke
Settings: outpat ients
Intervention: hydroxyurea
Comparison: observat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Observation Hydroxyurea
Pain alteration
Follow-up: NA
Outcome not reported NA
Life- threatening
illness
Follow-up: 15 months
See comment See comment NA 22
(1 study)
⊕©©©
very low3,4
No signif icant dif f er-
ences between groups
in terms of ACS, blood
transfusions required or
acute splenic sequestra-
t ion
Death during the study
Follow-up: 15 months
No deaths occurred No deaths occurred NA 22
(1 study)
⊕©©©
very low3,4
M easures of HbF
Follow-up: 15 months
See comment See comment NA 22
(1 study)
⊕©©©
very low3,4
There was a signif icant
increase in HbF in the
hydroxyurea group com-
pared to the observat ion
group1.
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M easures of ANC
Follow-up: 15 months
See comment See comment NA 22
(1 study)
⊕©©©
very low3,4
There was a signif icant
decrease in ANC in the
hydroxyurea group com-
pared to the observat ion
group1.
Quality of Life
Follow-up: NA
Outcome not reported2 NA
Adverse events or tox-
icity: dif ferences in
rates of specif ic ad-
verse events
Follow-up: 15 months
See comment See comment NA 22
(1 study)
⊕©©©
very low3,4
No signif icant dif f er-
ences between groups in
terms of transient neu-
tropenia, ret iculocytope-
nia, parasite infestat ion,
headache and dizziness
The basis for the assumed risk is the event rate in the control group unless otherwise stated in the comments and footnotes. The corresponding risk (and its 95% conf idence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ACS: acute chest syndrome; ANC: absolute neutrophil counts; CI: conf idence interval; HbF: f etal haemoglobin; NA: not applicable; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Median values reported so data cannot be entered into analysis.
2. Outcome was not collected or presented due to early term inat ion of study.
3. Downgraded twice due to serious imprecision: study term inated early with only 22 of target 100 part icipants recruited.
Small number of part icipants included in f inal analyses which are likely to be underpowered.
4. Downgraded once due to applicability: only children with HbSS or HbSβº -thalassemia were included therefore results are
not applicable to adults or individuals with HbSC genotype.
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Hydroxyurea compared with no hydroxyurea for sickle cell disease
Patient or population: adults and children with sickle cell disease
Settings: outpat ients
Intervention: hydroxyurea
Comparison: no hydroxyurea
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No hydroxyurea Hydroxyurea
Pain alteration
Follow-up: NA
Outcome not reported NA
Life- threatening
illness
Follow-up: NA
Outcome not reported NA
Death during the study
Follow-up: 11 months
No deaths occurred No deaths occurred NA up to 44
(1 study)1
⊕©©©
very low2,3,4
M easures of HbF
Follow-up: 24 weeks
See comment See comment NA up to 44
(1 study)1
⊕©©©
very low2,3,4
There was a signif icant
increase in HbF in the
hydroxyurea group com-
pared to the no hydrox-
yurea group1.
M easures of ANC
Follow-up: 24 weeks
See comment See comment NA up to 44
(1 study)1
⊕©©©
very low2,3,4
There was no signif icant
dif f erence in ANC be-
tween treatment groups
1.
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Quality of life
Follow-up: NA
Outcome not reported NA
Adverse events or tox-
icity
Follow-up: 11 months
See comment See comment NA up to 44
(1 study)1
⊕©©©
very low2,3,4
Vaso-occlusive
pain crises, headache /
migraine, upper respira-
tory infect ion, skin rash
diarrhoea and abdomi-
nal pain were the most
common adverse events
during the trial and these
events were evenly dis-
tributed across treat-
ment groups (not sepa-
rated by group)
The basis for the assumed risk is the event rate in the control group unless otherwise stated in the comments and footnotes. The corresponding risk (and its 95% conf idence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ANC: absolute neutrophil counts; CI: conf idence interval; HbF: f etal haemoglobin; NA: not applicable; RR: risk rat io.
GRADE Working Group grades of evidence.
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Due to the factorial design of the study (22 part icipants randomised to a treatment arm including hydroxyurea and 22
randomised to a treatment arm without hydroxyurea), results are not entered into analysis. All results of this trial are
considered exploratory (CHAMPS 2011).
2. Downgraded once due to indirectness: factorial design of the study makes comparison of hydroxyurea to no hydroxyurea
indirect.
3. Downgraded once due to imprecision and risk of bias: study was term inated early with only 44 out of 188 part icipants
recruited and outcome data is presented for only those who completed each follow-up t ime.
4. Downgraded once due to applicability: part icipants with HbSC were included therefore results are not applicable to
individuals with HbSS or HbSβº -thalassemia genotypes.
2
9
H
y
d
ro
x
y
u
re
a
(h
y
d
ro
x
y
c
a
rb
a
m
id
e
)
fo
r
sic
k
le
c
e
ll
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
Eight randomised controlled studies were eligible for inclusion in
this review, with a total of 899 children and adults with sickle
cell disease (SCD) (BABY HUG 2011; Belgian Study 1996;
CHAMPS 2011; Jain 2012;MSH 1995; SCATE 2015; SWiTCH
2012; TWiTCH 2016). The studies included in the review made
the following comparisons: hydroxyurea compared to placebo
(BABY HUG 2011; Belgian Study 1996; Jain 2012; MSH 1995);
hydroxyurea compared to no hydroxyurea (CHAMPS 2011); hy-
droxyurea and phlebotomy compared to transfusion and chela-
tion for the prevention of primary or secondary stroke (SWiTCH
2012, TWiTCH 2016); and hydroxyurea compared to observa-
tion for participants at an increased risk of stroke (SCATE 2015).
The randomised studies comparing hydroxyurea with placebo
(Belgian Study 1996; Jain 2012; MSH 1995) all showed a de-
crease in pain crises (albeit with slightly different criteria) in adults
and children with sickle cell anaemia. The BABYHUG study also
showed decreased rates of pain in the hydroxyurea group compared
to placebo. This widening of inclusion criteria has had an im-
portant role in increasing indications for and use of hydroxyurea.
Two studies comparing transfusion and hydroxyurea showed that
transfusion was more effective in preventing ’serious’ sickle-related
pain (SWiTCH 2012; TWiTCH 2016), but there was no differ-
ence in all pain events between the two groups, as reported by one
study (SWiTCH 2012).
Rates of acute chest syndrome (ACS) were decreased in those tak-
ing hydroxyurea when compared with those taking placebo and
this was true in adults (MSH 1995) and children (BABY HUG
2011; Jain 2012). Similar decreases were seen in transfusion rates,
a surrogate for life-threatening illness (BABY HUG 2011; Jain
2012; MSH 1995). Hydroxyurea did not prevent rates of hep-
atic or splenic sequestration when compared with placebo (BABY
HUG 2011; MSH 1995).
The role of hydroxyurea compared with transfusion in the preven-
tionof stroke has been investigated in two studies (SWiTCH 2012;
TWiTCH 2016). The SWiTCH study included people with a
previous stroke who had received at least 18 months of transfu-
sion and randomised between ongoing transfusion therapy and
hydroxyurea and phlebotomy (SWiTCH 2012). Treatment with
hydroxyurea and phlebotomywas not expected to be as effective as
transfusion in the reduction of secondary stroke but was expected
to improve liver iron loads so a composite primary end point was
used including stroke recurrence and liver iron concentration. In
the 133 participants there were no strokes in the transfusion and
chelation group but seven strokes (10%) in the hydroxyurea and
phlebotomy group without concomitant improvement liver iron
concentration leading to early trial closure.Hydroxyurea and phle-
botomy were not as effective as transfusion for secondary stroke
prevention. In the TWiTCH study, hydroxyurea was compared
with transfusion in children with abnormal transcranial doppler
(TCD) velocities who had received transfusion for at least one
year and had no evidence of vasculopathy on magnetic resonance
angiography (MRA) (TWiTCH 2016). Hydroxyurea was as ef-
fective as transfusion in preventing further stroke and final TCD
velocity was lower in the hydroxyurea group. These findings are
supported by observational data showing that in a non-trial situa-
tion in children with abnormal TCDs who have normalised with
transfusion, hydroxyurea can be used to maintain normal TCDs
(Bernaudin 2016).
In the randomised studies included in this analysis there was no
statistically significant differences in mortality between any treat-
ment and control group. Follow-up from cohorts from the MSH
study have been published at nine and 17.5 years (MSH 1995),
although randomisation ceased after trial closure and participants
could choose whether to take hydroxyurea or not (Steinberg 2003;
Steinberg 2010). These follow-up studies both confirmed reduced
mortality in the group taking hydroxyurea although the analysis
was according to cumulative exposure to hydroxyurea and not the
original randomisation. Further supporting evidence for reduced
mortality with hydroxyurea comes from a prospective non-ran-
domized trial (LasHS) from Greece with 17 years of follow-up
which showed improved probability of 10-year survival in par-
ticipants who were treated with hydroxyurea (Voskaridou 2010).
These results should be treated cautiously as the participants were
not randomised and the analysis of mortality in an observational
study is more complex.
In terms of chronic organ damage; there were no statistically sig-
nificant differences in renal and splenic function (the primary out-
comes of BABY HUG 2011). Hydroxyurea had no significant ef-
fect on glomerular filtration rate over the two years of treatment,
but it did improve urine concentrating ability and there was less
renal enlargement in the hydroxyurea-treated groups.
Several of the randomised studies showed a statistically significant
increase in HbF levels in the groups treated with hydroxyurea,
in keeping with the mechanism of action of the drug. This was
seen both in participants treatedwith themaximum-tolerated dose
(MTD) of hydroxyurea (MSH 1995; SWiTCH 2012; TWiTCH
2016) and those treated with a standard dose (BABY HUG 2011;
Jain 2012). A statistically significant increase in Hb level was seen
in studies which compared hydroxyurea to placebo (BABY HUG
2011; Belgian Study 1996; CHAMPS 2011; MSH 1995; Jain
2012; SCATE 2015) and a decrease in haemolytic markers with
hydroxyurea treatment was seen in some of the studies (BABY
HUG 2011; Jain 2012; MSH 1995).
Those studies which used dose escalation to the MTD (MSH
1995; SCATE 2015; SWiTCH 2012; TWiTCH 2016), showed
greater rates of cytopenias, which are expected as the dose of the
drug is raised. The MSH study showed increased haematological
toxicity resulting in a dose reduction in the hydroxyurea group as
compared with placebo, but there were no infections related to
neutropenia or bleeding episodes due to thrombocytopenia (MSH
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1995). Similarly, the SWiTCH study showed significantly in-
creased rates of reticulocytopenia, neutropenia and anaemia in the
hydroxyurea group, compared with transfusion (SWiTCH 2012).
The BABY HUG study which used a standard dose of 20 mg/kg
of hydroxyurea showed an increase in neutropenia (in terms of ab-
solute neurophil count) in the hydroxyurea group but no increase
in events of thrombocytopenia and no increase in the number of
infections (BABY HUG 2011). There are no randomised studies
comparing the effect of using a standard dose versus dose escala-
tion to theMTD. Clearly, with careful laboratory monitoring and
appropriate patient education, cytopenia should rarely represent a
major issue as demonstrated.
In the randomised studies comparing hydroxyurea with placebo
there was no increase in adverse events related to hydroxyurea in-
cluding hair loss, skin rash, fever and gastro-intestinal disturbance.
In addition, in the MSH study there was no increase in the in-
cidence of leg ulcers and avascular necrosis in those treated with
hydroxyurea. This is important as they have both been associated
with hydroxyurea use in observational reports and leg ulcers are
associated with hydroxyurea use in people with myeloproliferative
disease. Furthermore, observational data looking at 15 years of
hydroxyurea use from infancy has not shown any concerns about
safety (Hankins 2014), although as with the mortality data this is
not based on randomised data and should be treated with caution.
Overall completeness and applicability of
evidence
Evidence from the eight included studies is extensive and for four
of the studies it is reported across many publications (BABYHUG
2011; MSH 1995; SWiTCH 2012; TWiTCH 2016). Further-
more as discussed in the Summary of main results, evidence from
these randomised studies is generally supported by longer-term or
observation evidence (or both).
There are still questions about the impact of hydroxyurea on the
chronic organ damage associated with SCD. Results from the
BABY HUG study showed improved urine concentrating abil-
ity and less renal enlargement in the hydroxyurea-treated groups.
These results suggest that hydroxyurea may have some beneficial
effect on renal function, but these results do not automatically
translate into clinical benefit (BABY HUG 2011). The long-term
effect of hydroxyurea therefore, would benefit from further study,
including effects on brain development, IQ, growth and develop-
ment, as well as the prevention and management of chronic organ
damage.
As a chemotherapeutic agent, the cytostatic effects of hydroxyurea
are different from those of radiation, alkylating agents and other
anti-cancer drugs, many of which are known to increase the risk
of development of either leukaemia or cancer. Long-term follow-
up of people taking hydroxyurea for other diagnoses, including
polycythaemia rubra vera (Berk 1995; Fruchtman 1994; Najean
1997), essential thrombocythaemia (Sterkers 1998) and cyanotic
heart disease (Triadou 1994), has shown no increase in malignan-
cies in those with normal bonemarrows and no significant increase
in the other groups. There has been no evidence of malignancy in
those with SCD treated with hydroxyurea in large observational
studies (Steinberg 2010; Voskaridou 2010). Small numbers of case
reports have reported myelodysplasia or acute leukaemia in people
with SCD treated with hydroxyurea and two of these have been
associated with 17p deletions. This is of interest as 17p deletions
have also been associated with the development of myelodyspla-
sia or acute leukaemia in people with myeloproliferative disease
treated with hydroxyurea (Aumont 2015; Baz 2012). In vitro work
has not shown increased chromosome breakages or decreased re-
pair in people with SCD on hydroxyurea (McGann 2011).
Concerns have been raised about whether hydroxyurea is associ-
ated with abnormal spermatogenesis and teratogenic effects but
there are few data to confirm or refute that. There is a theoretical
risk of hydroxyurea affecting sperm development and abnormal
spermatogenesis has been shown in animals treated with hydrox-
yurea. Sperm abnormalities, including oligospermia and azoosper-
mia, have been shown in males with SCD taking hydroxyurea,
but it is not clear if these are due to the hydroxyurea as similar
abnormalities have been described in males with SCD not taking
hydroxyurea. One small study compared semen analysis before,
during and after hydroxyurea treatment and showed semen pa-
rameters were affected whilst on hydroxyurea and did not seem to
recover quickly (Berthaut 2008). This included only small num-
bers of individuals and needs further investigation.
Evidence of adverse outcomes and teratogenic effects in humans
exposed to hydroxyurea in utero is limited. There is case report
evidence of women with malignant disease taking hydroxyurea
through pregnancywith no adverse effects on the fetus and 17-year
follow-up of the MSH study has shown no adverse fetal outcomes
inmales or females takinghydroxyurea at conception (Ballas 2009)
(Table 5) . An expert panel report evaluating the toxicity of hydrox-
yurea has led to recommendations that hydroxyurea is stopped in
men and women who are trying to conceive and in breastfeeding
women (National Toxicology Program 2008). The risks of stop-
ping hydroxyurea whilst attempting conception should be care-
fully discussed with the individual.
The CHAMPS study was the only study to include participants
with HbSC (CHAMPS 2011). It was not powered to measure
efficacy and terminated early due to low enrolment so it is not
possible to make conclusions about the efficacy of hydroxyurea
in prevention of pain episodes in people with HbSC. Observa-
tional data suggest it may be safe and effective in selected indi-
viduals, but this needs further study with a phase 3 randomised
study (Luchtman-Jones 2016). A total of 165 people with HbS/
B+thalassaemia were included in one observational study but only
44 received hydroxyurea and efficacy on this subgroup was not
presented separately (Voskaridou 2010).
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Quality of the evidence
We judged the quality of the evidence for the comparison ’Hy-
droxyurea compared to placebo’ to bemoderate formost outcomes
and low for quality of life and adverse events, where data were
more limited and imprecise (Summary of findings for the main
comparison).
Similarly, we judged the quality of the evidence for the compari-
son ’Hydroxyurea and phlebotomy compared to transfusion and
chelation for participants with SCD and risk of stroke’ to be mod-
erate (life-threatening illness and measures of fetal haemoglobin
and neutrophil counts) or low quality (pain alteration, deaths dur-
ing the study and adverse events) where data were more limited
and imprecise (Summary of findings 2).
The studies contributing the majority of the evidence to these
comparison were large, generally well designed and of low risk of
bias (BABY HUG 2011; MSH 1995; SWiTCH 2012; TWiTCH
2016). These studies recruited only individuals with haemoglobin
SS genotype (HbSS) or haemoglobin Sβº (HbSβº) thalassemia
genotypes, therefore, results are not applicable to those with hae-
moglobin SC genotype (HbSC) genotypes. Furthermore, for the
two most recently completed studies, results for secondary out-
comes such as neuropsychological status, growth and develop-
ment, functional evaluations and neurocognitive evaluations have
not yet been reported. Any results relevant to this review from
further publications will be included in this review.
For the other two comparisons in the review ’Hydroxyurea com-
pared to observation for participants with SCD and risk of stroke’
and ’Hydroxyurea compared to no hydroxyurea for participants
with SCD,’ evidencewas limited andof very lowquality (Summary
of findings 3; Summary of findings 4). Only a single study con-
tributed to each outcome and both of these studies are likely un-
derpowered due to early termination after recruiting only around
20% of their target participants. Furthermore, due to the factorial
design of one of the studies (CHAMPS 2011), a direct comparison
between hydroxyurea and a control treatment was not possible so
all results for this comparison must be interpreted as indirect.
Potential biases in the review process
A rigorous methodological approach was applied to the review
and a comprehensive search strategy was employed as outlined in
Electronic searches, therefore, we do not believe that our method-
ological approach has introduced any bias into the review.
Given the designs of some of the studies included in this review
(e.g. cross-over, factorial) and differing study-defined definitions
of the outcomes of interest to this review, in many instances we felt
it would be more appropriate to summarise results narratively or
perform separate analyses rather than attempting to adjust original
results in order to perform meta-analysis.
We encourage particular caution when interpreting results of the
outcome ’adverse events or toxicity’, as it is difficult to distinguish
between adverse reactions (i.e. adverse events which are definitely
drug-related) and other adverse events which may be sickle- or
transfusion-related. For completeness, we have reported all “ad-
verse events” or “adverse effects” as they are reported in the study
publications, regardless of any noted relationship to treatment.
Agreements and disagreements with other
studies or reviews
As described earlier in this section, there have been several studies
supporting the findings of this review. In addition to these, nu-
merous reviews and other studies discussing the role of hydrox-
yurea in SCD are available but this is the only Cochrane Review of
the topic. A report from the National Institutes of Health (NIH)
reviewed 414 studies reporting on the role of hydroxyurea in SCD
(published up until July 2014) included five of the randomised
studies included in this review (NIH 2014). In some cases in the
NIH review, where a literature search was not conducted or was
insufficient, the panel relied on their cumulative expertise and
knowledge tomake consensus-panel recommendations as outlined
below.
Strong recommendations with high-quality evidence
• In adults with sickle cell anaemia who have three or more
sickle cell-associated moderate to severe pain crises in a 12-
month period, treat with hydroxyurea.
• In infants of nine to 42 months with sickle cell anaemia,
offer treatment with hydroxyurea regardless of clinical severity to
reduce SCD-related complications (e.g. pain, dactylitis, ACS,
anaemia).
• To ensure proper use of hydroxyurea and maximize benefits
and safety, use an established prescribing and monitoring
protocol.
Strong recommendations with moderate quality
evidence
• In adults with sickle cell anaemia who have sickle cell-
associated pain that interferes with daily activities and quality of
life, treat with hydroxyurea.
• In adults with sickle cell anaemia who have a history of
severe or recurrent ACS (or both), treat with hydroxyurea.
• In adults with sickle cell anaemia who have severe
symptomatic chronic anaemia that interferes with daily activities
or quality of life, treat with hydroxyurea.
The group also made an additional moderate recommendation
with moderate-quality evidence that children over 42 months and
adolescents with sickle cell anaemia should be offered treatment
with hydroxyurea regardless of clinical severity to reduce SCD-
related complications (e.g. pain, dactylitis, ACS, anaemia). There
were additional moderate and weak recommendations with low-
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and very low-quality evidence and a consensus panel recommen-
dation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The initial randomised studies showed efficacy of hydroxyurea in
decreasing pain episodes and other acute complications in adults
and children with HbSS and HbSßº-thalassemia (Belgian Study
1996; Jain 2012; MSH 1995). This led to recommendations that
hydroxyurea should be offered to this group of individuals. The
evidence of similar efficacy in a group of infants not selected for
severity (BABYHUG2011) is suggestive that all infantswith sickle
cell anaemia may benefit from hydroxyurea. This has led to rec-
ommendations that it should be offered to all children with sickle
cell anaemia regardless of clinical severity (NIH 2014) and has led
to an increased use of hydroxyurea, particularly in children. There
is still insufficient evidence on the long-term benefits of hydrox-
yurea, particularly in the prevention of the chronic complications
of SCD and also insufficient evidence about the long-term risks
of hydroxyurea including its effects on fertility and reproduction.
Hydroxyurea is the only licensed drug for the treatment of SCD
and its efficacy in reducing the acute complications of the disease
and potential risks of use should be discussed with all individuals
with SCD and the families of children with SCD, allowing them
to take an informed decision about its use.
There is insufficient evidence to recommend its routine use in
those individuals with genotypes other than sickle cell anaemia,
but its potential benefits and risks of use should be discussed with
those with a severe disease phenotype.
Randomised comparisons of hydroxyurea and transfusion showed
that hydroxyurea seems to be as effective as transfusion in prevent-
ing stroke in children with sickle cell anaemia and abnormal TCD
velocities who have received at least one year of transfusion ther-
apy and have no evidence of vasculopathy on MRA. Hydroxyurea
does not seem to be as effective as transfusion therapy in prevent-
ing stroke in children with sickle cell anaemia who have already
experienced a stroke. Hydroxyurea should be offered to children
in the former group (sickle cell anaemia, abnormal TCD velocity,
normal MRA, received at least one year of transfusion therapy) as
an alternative to long-term transfusion therapy.
There is insufficient evidence on whether to prescribe a standard
dose or dose escalation to the MTD. All individuals treated with
hydroxyurea should remain in long-term follow-up, which should
include regular blood monitoring.
Implications for research
Many questions remain unanswered relating to the role of hydrox-
yurea in SCD (as discussed below). All of these questions need to
be addressed by appropriately structured randomised controlled
studies. However, there is a need for international agreement on
a baseline common data set which should be collected in such
studies so that they can be analysed later using meta-analysis tech-
niques, as well as the need for standardised and validated measures
for sickle painful crisis and quality of life in people with SCD.
The continued long-term follow-up of the participants of the
MSH and BABY HUG studies, with regular reporting of out-
comes, is welcomed (BABY HUG 2011; MSH 1995). Particular
issues for future studies include:
1. the impact of hydroxyurea on the chronic complications of
SCD;
2. the role of hydroxyurea in the management of specific hard
to treat complications of SCD of all ages;
3. study of the long-term toxicity profile of hydroxyurea in
SCD;
4. the impact of low (15 mg/kg per day) or medium dose (20
mg/kg per day) hydroxyurea dosage in SCD versus dose
escalation to maximum tolerated dose;
5. role of hydroxyurea in developing countries;
6. the impact of hydroxyurea in genotypes other than HbSS.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
BABY HUG 2011
Methods Randomised, double blind (participant, investigator), placebo control, parallel assign-
ment, efficacy study conducted at 13 centres in the USA
Participants Children aged 9 months to 18 months with SCD (HbSS or HbSßº-thalassemia) irre-
spective of clinical severity. Exclusion criteria were transfusion within 2 months, height,
weight or head circumference below the 5th percentile, mental development index less
than 70 or abnormal TCD ultrasound velocity
193 randomised, 96 participants to hydroxyurea and 97 to placebo
Mean (SD) age: hydroxyurea group : 13.6 (2.7) months, placebo group: 13.5 (2.8)
months
187 (97%) with HbSS genotype, 109 (56%) females
Interventions Hydroxyurea (20 mg/kg/day) versus placebo for 24 months.
Outcomes Primary outcomes: spleen function (decline in splenic uptake); and glomerular filtration
rate with 99mTc-diethyl-enetriaminepentaacetic acid plasma clearance.
Secondary outcomes: ratio of nuclear decay counts in the spleen and liver; proportion
of red blood cells containing pits or Howell-Jolly bodies; renal function; growth; and
development (including neuro-developmental assessment)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The telephone randomisation schedule was
developed by the medical co-ordinating
centre
Allocation concealment (selection bias) Low risk Centralised telephone randomisation was
used.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Some secondary outcomes reported for
only the individuals who completed the
study but ITT approach taken for primary
outcomes (viamultiple imputation) and sa-
fety outcomes so risk of bias judged to be
low
Selective reporting (reporting bias) Low risk All outcomes well defined in the methods
and reported well in the results
Other bias Low risk None identified.
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BABY HUG 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, caregivers and medical coor-
dinating centre staff were masked to treat-
ment allocation via packaging and treat-
ment of the same appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk An unmasked “primary endpoint person”
monitored laboratory values and assisted
clinical management. Other outcome as-
sessors (e.g. those reading the liver-spleen
scans)
Belgian Study 1996
Methods Randomised placebo-controlled cross-over study conducted in a single centre in Belgium
Participants 25 children with HbSS genotype, age 2 - 22 years (median 9 years) with > 3 vaso-
occlusive events reported in preceding 12 months and/or history of CVA off transfusion
(severe alloimmunisation or compliance), ACS, ASS
Interventions Hydroxyurea 20 mg/kg/day rising to 25 (unless toxic cytopenia) versus placebo. Treat-
ment period was for 6 months
Outcomes Number of hospitalisations.
Number of inpatient days.
FBC.
HbF%.
Notes Data are not presented in a way that results can be included in the review so results are
presented narratively
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “drawing sealed envelopes, pa-
tients were randomly allocated to one of the
following treatment sequences”, therefore
the generation of the treatment sequence
are not clear from this statement
Allocation concealment (selection bias) Unclear risk Described as “drawing sealed envelopes, pa-
tients were randomly allocated to one of the
following treatment sequences”, therefore
the allocation of the treatment sequence are
not clear from this statement
45Hydroxyurea (hydroxycarbamide) for sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Belgian Study 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 participants who were excluded from the
analysis due to their failure to attend the
monthly evaluation at 4 - 5 months. There
was no discussion of whether or not an ITT
analysis was used so the risk is unclear
Selective reporting (reporting bias) High risk A planned outcome (number of days in
pain) was dropped from analysis due to dif-
ficulty in obtaining information to inform
this analysis from participants
Other bias Low risk Unclear if a washout periodwas used in this
cross-over study but tests for period effects
and carry-over effect were not significant so
the risk of bias in the cross-over design is
low
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The hospital pharmacy provided the treat-
ment and placebo for each participant and
both were described as “indistinguishable,
” however the physician was aware of the
treatment schedule because of the difficulty
of blinding the attending physician to the
treatment received. Unclear if this could
have influenced results
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
CHAMPS 2011
Methods Randomised multicentre, phase II, double blind placebo-controlled study
Participants Eligible participants over the age of 5 years with HbSC and at least 1 vaso-occlusive
event in the previous 12 months (but none in the 4 weeks prior to study entry)
44 participants randomised; 11 to each treatment group (see ’Interventions’)
Mean age: 13.6 years (range 5 - 53 years), 43% females.
Interventions Participants randomised to 1 of 4 arms in a factorial design:
1. hydroxyurea (20 mg/kg/day) and magnesium (0.6 mmol/kg/day in 2 doses);
2. hydroxyurea (20 mg/kg/day) and placebo;
3. placebo and magnesium (0.6 mmol/kg/day in 2 doses);
4. placebo and placebo.
Outcomes Primary outcome: proportion of hyperdense red blood cells at 8 weeks
Secondary outcomes: central laboratory evaluations (including measurements of red cell
density, HbF, red cell cation content, KCl co-transport and Gardos channel activity,
46Hydroxyurea (hydroxycarbamide) for sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CHAMPS 2011 (Continued)
cell adhesion to endothelial cells and laminin, and erythrocyte membrane phosphatidyl
serine (PS exposure)) at baseline (twice) and weeks 8, 16, 24, and 44
Participants were evaluated at 2 or 4 week intervals for 11 months (15 visits)
Notes The study was not designed to measure efficacy and all analyses were considered ex-
ploratory
The study was terminated early due to low enrolment after 44 participants had been
randomised (target 188)
Due to factorial design, no data can be entered into analysis and results for hydroxyurea
groups (groups 1 and 2) compared to no hydroxyurea groups are summarised narratively
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A sequential allocation algorithm (i.e. min-
imisation) was used due to small numbers
within each strata (site and age group)
Allocation concealment (selection bias) Unclear risk No information provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk 36 out of 44 participants completed 8
weeks and 22 out of 44 completed 44
weeks. Only those who completed the fol-
low-up time were included in analysis (8
weeks for primary endpoint and 44 weeks
for secondary endpoints). This is not an
ITT approach
Selective reporting (reporting bias) Low risk Outcome defined in the methods section
well described in the results section. Study
was not designed to measure efficacy
Other bias Low risk Study terminated early after only 44 of
planned sample size of 188 were recruited.
However, the study was not designed to
measure efficacy and performed only ex-
ploratory analyses therefore the early termi-
nation is unlikely to have introduced bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All tabletswere ’over-capsulated’ to disguise
appearance.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
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Jain 2012
Methods Double-blind randomised controlled study conducted in a tertiary hospital in Nagpur
City, India
Participants Indian children between the ages of 5 and 18 years with severe manifestations (defined
as 3 or more blood transfusions or VOC requiring hospitalisation per year) despite high
HbF
Exclusion criteria included seropositivity for HIV or chronic illness
60 participants randomised; 30 to each treatment group.
53% females (16 females per group).
Mean (SD) age - hydroxyurea group: 12.73 (4.4) years, placebo group: 11.73 (4.08)
years
Interventions Hydroxyurea (fixed dose 10 mg/mg/day) compared to placebo for 18 months
Outcomes Primary outcome: frequency of VOC per participant per year.
Secondary outcomes: frequency of blood transfusions, hospitalisations and HbF levels
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using ran-
domisation tables.
Allocation concealment (selection bias) Unclear risk No information provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed 18-months fol-
low-up and were included in analysis
Selective reporting (reporting bias) Low risk No protocol available, outcomes defined in
the methods reported well in the results
Other bias Low risk None identified.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded with placebo
tablets of identical appearance. The clin-
ician who assessed participants were not
aware of treatment arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The laboratory technician and the clinician
who assessed participants were not aware of
treatment arm
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MSH 1995
Methods Randomised multicentre parallel, double-blind placebo-controlled study. Conducted in
the USA and Canada across 21 sites
Participants Adults over 18 years of age with HbSS genotype who had reported more than 3 ’crises’
to treating physician in the preceding 12 months and who had < 15% HbA. Exclusions
included: HbA > 15%, pregnancy, opiate addiction, other potent anti-sickling agents,
cytopenia, CVA in the preceding 6 years, HIV antibody +, prior hydroxyurea therapy
152 randomised to hydroxyurea and 147 given placebo.
Interventions Hydroxyurea starting at 15 mg/kg/day rising 12-weekly by 5 mg/kg/day unless marrow
depression (then cessation of drug until recovery and restarted at 2.5 mg/kg/day lower,
i.e. MTD) compared to placebo for 2 years
Outcomes Primary outcome: pain events - attending hospital > 4 hours & parenteral opiate treat-
ment.
Secondary outcomes: ’crises’ including ACS, CVA, priapism etc, daily pain charts, time
to first and second crisis, FBC, F cells & Hb F%, dense cells
Notes 93% follow-up at 2 years, treatment stopped in 14 hydroxyurea and 6 placebo partici-
pants
Due to beneficial treatment effects, the study was stopped at a mean follow-up of 21
months, before the planned 24 months of treatment had been completed for all partici-
pants
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment assignments were made cen-
trally using a computer programme to gen-
erate separate, randomised block assign-
ment schedules for each clinic
Allocation concealment (selection bias) Unclear risk There was no clear discussion on allocation
concealment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals from the study were well doc-
umented, all participants included in analy-
sis in an ITT approach in the primary pub-
lications but later reported outcomes (such
as quality of life) reported only for those
who contributed data
Selective reporting (reporting bias) Low risk All outcomes well defined in the methods
and reported well in the results
Other bias Low risk None identified.
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MSH 1995 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated as double-blind (physician and par-
ticipant), where treatment was assigned in
combinations of identically appearing cap-
sules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk There was no clear discussion on blinding
of outcome assessors
SCATE 2015
Methods Phase III randomised, partially masked (outcome assessors) multicentre study conducted
in 3 centres in the USA, Jamaica and Brazil between May 2012 and August 2013
Participants Children with SCA and conditional TCD ultrasound velocities (170 cm - 199 cm per
second)
Exclusion criteria were prior abnormal TCD velocities or clinical stroke, red blood cell
transfusion within 2 months of enrolment, concurrent use of another anti-sickling med-
ication or contraindication to hydroxyurea therapy (allergy, pregnancy, renal insuffi-
ciency)
22 participants randomised, 11 to each treatment group.
Mean age (SD): hydroxyurea group: 6.2 (2.4) years, observation group: 6.6 (1.5) years
64% females, 7 per group. 21 participants with HbSS and 1 with HbSβº-thalassemia
Interventions Hydroxyurea (starting at 20 mg/kg/day escalated to a maximum of 35 mg/kg/day) com-
pared to standard treatment (observation)
Outcomes Primary outcome: conversion to abnormal maximum abnormal TAMV
Secondary outcomes: changes in serial TCD velocities.
Indicence of acute events including stroke.
Health-related quality of life (planned but not recorded, see ’Selective reporting’ below)
Notes The planned length of follow-up was 30 months but the study was terminated early after
15 months of follow-up due to slow participant accrual and the unlikelihood of meeting
the trial recruitment target (100) and the primary endpoint
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using an
adaptive blocked algorithm
Allocation concealment (selection bias) Low risk Central pharmacy distribution of alloca-
tions.
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SCATE 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers screened, randomised and num-
ber receiving randomised treatment re-
ported. Analysis conducted using an ITT
approach
Selective reporting (reporting bias) High risk A planned outcome (health-related quality
of life) was not analysed or presented as the
outcome was not sufficiently collected due
to early study termination
Other bias High risk Study terminated early after only 22 of
planned sample size of 100 were recruited
therefore study is likely to be statistically
underpowered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel could not be
masked to treatment allocation by de-
sign (hydroxyurea compared to observation
only). The primary outcome (conversion
to abnormal TAMV) was objective and de-
termined by masked outcome assessors so
lack of blinding of participants and person-
nel is unlikely to have affected results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All TCD site examiners, central review-
ers were masked and site clinicians were
masked to participants TCD results
SWiTCH 2012
Methods Phase III, multicentre, single masked (outcome assessors), non-inferiority study con-
ducted across 26 paediatric sites in the USA
Participants Participants with previous clinical stroke, aged 7 to 17 years, PRBC transfusions for at
least 18 months and transfusional iron overload
No specific exclusion criteria stated.
133 participants were randomised; 67 randomised to hydroxyurea treatment and 66 to
standard treatment
Mean (SD) age at study enrolment in years: hydroxyurea group 13.0 (4.0) years, standard
treatment group 13.3 (3.8) years
132 out of 133 participants with HbSS genotype, 61 females (46%)
Interventions Hydroxyurea starting at 20 mg/kg/day escalated to MTD and phlebotomy compared to
standard treatment (transfusions and chelation) for 30 months
Outcomes The primary outcome of the trial was a composite outcome. This involved occurrence
of a secondary stroke and quantitative liver iron level change from baseline
Secondary outcomes included quality of life, non-stroke neurological events, other SCD-
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SWiTCH 2012 (Continued)
related events, growth and development, functional evaluations, neurocognitive evalua-
tions, transfusion related complications, chelation related complications, hydroxyurea-
related complications, phlebotomy related complications, liver biopsy related complica-
tions and adverse and serious adverse events
Notes Numerous secondary outcomes were not reported in the main paper or any subsequent
papers
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study described as randomised, no further
details given.
Allocation concealment (selection bias) Unclear risk No details were given on allocation con-
cealment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals from treatment reported, all
individuals included in analysis in an ITT
approach
Selective reporting (reporting bias) High risk Many of the secondary outcomes (such as
growth and development, functional eval-
uations, neurocognitive evaluations) have
not yet been reported, If these results can
be included at a later date then this judge-
ment will be reconsidered
Other bias Low risk None identified.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel could not be
masked to treatment allocation by design
(hydroxyurea compared to transfusion).
The primary outcome (secondary stroke
and quantitative liver iron level change
from baseline) was objective and deter-
mined bymasked outcome assessors so lack
of blinding of participants and personnel is
unlikely to have affected results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The primary outcome (secondary stroke
and quantitative liver iron level change
from baseline) were determined by a group
of treatment masked neurologists and neu-
roradiologists
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TWiTCH 2016
Methods Multicentre phase III randomised open-label (partially masked) non-inferiority study
conducted at 26 paediatric hospitals and health centres in the USA and Canada
Participants Children aged 4 - 16 years with SCA and abnormal TCD ultrasound velocities (> 200
cm per second) if they had received 12 months of chronic transfusions
Exclusion criteria were documented clinical stroke, TIA or severe vasculopathy
121 participants were randomised; 60 randomised to hydroxyurea treatment and 61 to
standard treatment
Mean (SD) age at study enrolment in years: hydroxyurea group 9.5 (2.6) years, standard
treatment group 9.7 (3.2) years
119 out of 121 participants with HbSS genotype, 73 females (60%)
Interventions Hydroxyurea starting at 20 mg/kg/day escalated to MTD and phlebotomy compared to
standard treatment (transfusions and chelation) for 24 months
Outcomes Primary outcome: maximum TCD time averaged mean velocity on the index side (i.e.
the cerebral hemisphere with the higher mean arterial velocity at baseline assessment)
Secondary outcomes: TCD velocity on the non-index side, neurological events, new
brain lesions, hepatic iron overload, SCD-related events, treatment-related complication
(reported in this publication) neuropsychological status, quality of life and growth and
(to be reported in future publications)
Notes Study was terminated early at the first interim analysis when non-inferiority was demon-
strated, target sample size was met at early termination
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised block randomisation with
block size four, with stratification by site
and balanced by baseline age and TCD ve-
locity
Allocation concealment (selection bias) Low risk Central randomisation and treatment allo-
cation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers discontinuing the interventions
stated, all participants included in analysis
in an ITT analysis
Selective reporting (reporting bias) High risk Outcomes of neuropsychological status,
quality of life and growth were measured
but results are not yet published. If these
results can be included at a later date then
this judgement will be reconsidered
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TWiTCH 2016 (Continued)
Other bias Low risk Study was terminated early at the first in-
terim analysis when non-inferiority was
demonstrated, target sample size wasmet at
early termination so the study is adequately
powered to detect differences
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel could not be
masked to treatment allocation by design
(hydroxyurea compared to transfusion).
The primary outcome (maximum TCD
time averaged mean velocity) was objective
and determined by masked outcome asses-
sors so lack of blinding of participants and
personnel is unlikely to have affected results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All TCD examinations were read centrally
by observers blinded to treatment alloca-
tion and previous TCD results
ACS: acute chest syndrome
ASS: acute splenic sequestration
CVA: cerebro-vascular accident
Cytopenia: refers to either neutropenia or thrombocytopenia, anaemia is also a risk but was not reported
FBC: full blood count
HbA: adult haemoglobin
HbF: fetal haemoglobin
HbSβº: haemoglobin Sβºthalassaemia genotype
HbSC: haemoglobin SC genotype
HbSS: haemoglobin SS genotype
ITT: intention-to-treat
KCl: potassium chloride
MTD: maximum tolerated dose
PRBC: packed red blood cells
SCA: sickle cell anaemia
SCD: sickle cell disease
SD: standard deviation
TAMV: time averaged mean velocity
TCD: transcranial doppler
TIA: transient ischaemic attack
VOC: vaso-occlusive crisis
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Nood 2011 This is not a randomised study.
De Montalembert 2006 This study does not fulfil the inclusion criteria. The length of treatment was 8 days, the inclusion criteria
state that treatment should be at least 1 month
George 2013 This does not make a randomised comparison of hydroxyurea and placebo or standard treatment (the
randomised comparison is dosing schedules of hydroxyurea)
NCT00004492 This does not make a randomised comparison of hydroxyurea and placebo or standard treatment
NCT01848925 This study does not fulfil the inclusion criteria. The length of treatment was 7 days, the inclusion criteria
state that treatment should be at least 1 month
NCT01960413 This does not make a randomised comparison of hydroxyurea and placebo or standard treatment
NCT02149537 This is not an appropriate design to measure the effectiveness of hydroxyurea (cross-over design of low-
dose hydroxyurea compared to no treatment to monitor those at increased risk of infection)
Pushi 2000 This is not a randomised study.
Silva-Pinto 2007 This is not a randomised study.
Silva-Pinto 2014 This is not a randomised study.
Vichinsky 2013 This does not make a randomised comparison of hydroxyurea and placebo or standard treatment
Voskaridou 2005 This is not a randomised study.
Characteristics of studies awaiting assessment [ordered by study ID]
Anyanwu 2016
Methods Prospective, randomised, placebo-controlled, double-blinded phase III trial (NOHARM trial)
Participants Study participants will be recruited from the Mulago Hospital Sickle Cell Clinic (MHSCC) in Kampala, Uganda
Children aged 1 to 4 years with documented HbSS living in an area of meso-endemic malaria transmission
Interventions Hydroxyurea 20 ± 2.5 mg/kg/day compared to placebo
Outcomes Primary outcome: malaria incidence, defined as episodes of clinical malaria occurring over the 1-year randomised
study treatment period
Secondary outcomes: frequency of haematologic toxicities and AEs, relationships between hydroxyurea treatment
and fetal haemoglobin, soluble intracellular adhesion molecule-1, and nitric oxide levels, and between levels of these
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Anyanwu 2016 (Continued)
factors and risk of subsequent malaria
Notes Currently, only a protocol is available for the NOHARM study
We are unsure if this studymeets the inclusion criteria of the review of ’Type of Participants’ due to the study objectives
around determining the incidence of malaria in SCA individuals. We will make an assessment of the eligibility of the
population when study results are available
NCT02560935
Methods Randomised, double-blind, parallel group, dose-controlled study (SPRING)
Participants Participants with HbSS or HbSβº-thalassemia, S variant with baseline haemoglobin less than 10 g/dL or other sickle
cell syndromes apart from HbSC between the ages of 5 and 12 years, living in sub-Saharan Africa, without prior
overt stroke
Inclusion criteria for a ’non-elevated TCD group’ (participants who are not eligible to receive hydroxyurea therapy
but are willing to be following for a minimum of 3 years)
Interventions Hydroxyurea (moderate dose): 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 24 months
Hydroxyurea (low dose): 10 mg/kg/day (range 7 - 15 mg/kg/day) for 24 months
Outcomes Primary outcome: efficacy of moderate vs low-dose hydroxyurea therapy for primary stroke prevention
Secondary outcome: incidence of all-cause hospitalizations.
Secondary outcome: long-term safety of hydroxyurea therapy.
Notes Unclear if this is an appropriate design (dose-control) and population for the review (’non-elevated TCD group’)
Trial is ongoing (estimated completion date - December 2021), we will make an assessment of the eligibility of the
design and population when trial results are available
NCT02675790
Methods Randomised, double-blind, parallel group, dose-controlled study (SPRINT)
Participants Participants between the age of 1 and 18 years with SCA and a history of stroke up to 30 days before entry into the
study, living in sub-Saharan Africa
Interventions Hydroxyurea (moderate dose): 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 24 months
Hydroxyurea (low dose): 10 mg/kg/day (range 7 - 15 mg/kg/day) for 24 months
Outcomes Primary outcome: rate of clinical stroke recurrence.
Secondary outcome: incidence of all-cause hospitalisation.
Notes Unclear if this is an appropriate design (dose-control) and population for the review (participants can have already
received hydroxyurea treatment)
Study is ongoing (estimated completion date July 2019), we will make an assessment of the eligibility of the design
and population when study results are available
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AEs: adverse events
HbSβº: haemoglobin Sβºthalassaemia genotype
HbSC: haemoglobin SC genotype
HbSS: haemoglobin SS genotype
TCD: transcranial doppler
Characteristics of ongoing studies [ordered by study ID]
NCT01389024
Trial name or title NCT01389024: Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease (HUPrevent)
Methods Randomised, double-blind, parallel design, phase 2 study.
Participants Participants with HbSS or HbSβº-thalassemia aged between 9 and 48 months of age, with or without central
nervous system complications
Interventions Hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day;
placebo (sucrose) 0.2 mL/kg/day increased to max of 0.35 mL/kg/day
Outcomes Primary outcome: central nervous system complications (a composite of abnormally elevated cerebral blood
flow velocity as measured by TCD ultrasound, SCI, or stroke)
Secondary outcome: proportion of participants with severe adverse events attributed to study procedures
Starting date October 2011
Contact information Johns Hopkins University
Diane Weiss, BA (dweiss14@jhmi.edu)
James F. Casella, MD (jcasella@jhmi.edu)
Notes Estimated completion date October 2017 (final data collection date for primary outcome measure)
HbSβº: haemoglobin Sβºthalassaemia genotype
HbSC: Haemoglobin SC genotype
HbSS: Haemoglobin SS genotype
SCI: silent cerebral infarct
TCD: transcranial doppler
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D A T A A N D A N A L Y S E S
Comparison 1. Hydroxyurea versus placebo for participants with sickle cell disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain crises 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Mean annual crisis rate at
2 years (all crises)
1 Mean Difference (IV, Fixed, 95% CI) -2.80 [-4.74, -0.86]
1.2 Mean annual crisis rate
at 2 years (all crises requiring
hospitalisation)
1 Mean Difference (IV, Fixed, 95% CI) -1.50 [-2.58, -0.42]
1.3 Number of vaso-occlusive
crises after 18 months of
treatment
1 Mean Difference (IV, Fixed, 95% CI) -9.6 [-10.86, -8.34]
2 Proportion experiencing pain 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Proportion experiencing life
threatening events during study
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Acute chest syndrome 2 492 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.29, 0.63]
3.2 Hepatic sequestration 1 299 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.03, 3.06]
3.3 Stroke 2 492 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.12, 2.53]
3.4 Patients transfused 2 492 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.52, 0.82]
3.5 Splenic sequestration 1 193 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.36, 2.23]
4 Number of life-threatening
events during study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Blood transfusions 1 Mean Difference (IV, Fixed, 95% CI) -1.85 [-2.18, -1.52]
4.2 Hospitalisations 1 Mean Difference (IV, Fixed, 95% CI) -8.89 [-10.04, -7.74]
4.3Duration of hospitalisation
(days)
1 Mean Difference (IV, Fixed, 95% CI) -2.00 [-4.87, -3.13]
5 Deaths during the study 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 All deaths 3 552 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.08, 1.96]
5.2 Deaths related to SCD 3 552 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.09, 2.60]
6 Change from baseline in fetal
haemoglobin (HbF %)
1 Mean Difference (Fixed, 95% CI) Totals not selected
7 Fetal haemoglobin (HbF %)
after treatment
2 359 Mean Difference (IV, Fixed, 95% CI) 4.07 [2.95, 5.18]
8 Change from baseline in absolute
neutrophil count (x10³ per µL)
1 Mean Difference (Fixed, 95% CI) Totals not selected
9 Neutrophil response (10 /L)
after treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Neutrophils (x10 9/l) at
10 weeks
1 Mean Difference (IV, Fixed, 95% CI) -1.90 [-2.51, -1.29]
9.2 Neutrophils (x10 9/l) at 2
years
1 Mean Difference (IV, Fixed, 95% CI) -1.50 [-2.01, -0.99]
10 Change from baseline in
haemoglobin (g/L)
1 Mean Difference (Fixed, 95% CI) Totals not selected
11 Change from baseline in m
corpuscular volume (fL)
1 Mean Difference (Fixed, 95% CI) Totals not selected
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12 Change from baseline in white
blood cells (x10³ per µL)
1 Mean Difference (Fixed, 95% CI) Totals not selected
13 Change from baseline in
absolute reticulocyte count
(x10³ per µL)
1 Mean Difference (Fixed, 95% CI) Totals not selected
14 Change from baseline in
reticulocytes (%)
1 Mean Difference (Fixed, 95% CI) Totals not selected
15 Change from baseline in total
bilirubin (mg/L)
1 Mean Difference (Fixed, 95% CI) Totals not selected
16 Change from baseline in
platelet count (x10³ per µL)
1 Mean Difference (Fixed, 95% CI) Totals not selected
17 Haemoglobin (g/dL) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 At 10 weeks 1 299 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.19, 0.81]
17.2 At the end of the study 2 359 Mean Difference (IV, Fixed, 95% CI) 1.04 [0.82, 1.25]
18 Mean corpuscular volume (fL) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 At 10 weeks 1 Mean Difference (IV, Fixed, 95% CI) 12.30 [9.69, 14.91]
18.2 At 2 years 1 Mean Difference (IV, Fixed, 95% CI) 10.0 [7.34, 12.66]
19 Total bilirubin (mg/L) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
19.1 At the end of the study 2 359 Mean Difference (IV, Fixed, 95% CI) -1.56 [-1.90, -1.23]
20 Reticulocytes 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 Reticulocytes (10 /mm³)
at 18 months
1 Mean Difference (IV, Fixed, 95% CI) -0.66 [-0.90, -0.42]
20.2 Reticulocytes (10 /L) at
10 weeks
1 Mean Difference (IV, Fixed, 95% CI) -130.0 [-152.17, -
107.83]
20.3 Reticulocytes (10 /L) at
2 years
1 Mean Difference (IV, Fixed, 95% CI) -69.0 [-91.56, -46.
44]
21 Platelet count 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
21.1 Platelet count (10³/mm³)
at 18 months
1 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.16, 0.06]
21.2 Platelet count (x10 /L)
at 10 weeks
1 Mean Difference (IV, Fixed, 95% CI) -35.0 [-75.19, 5.19]
21.3 Platelet count (x10 /L)
at 2 years
1 Mean Difference (IV, Fixed, 95% CI) -24.0 [-51.88, 3.88]
22 Packed cell volume 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 Packed cell volume (%)
at 2 years
1 Mean Difference (IV, Fixed, 95% CI) 1.90 [0.85, 2.95]
23 F reticulocytes 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
23.1 F reticulocytes at 2 years 1 Mean Difference (IV, Fixed, 95% CI) 2.0 [0.18, 3.82]
24 F cells 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
24.1 F cells (%) at 2 years 1 Mean Difference (IV, Fixed, 95% CI) 13.0 [8.33, 17.67]
25 Red blood count 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
25.1 Red blood count
(10 /mm³) at 18 months
1 Mean Difference (IV, Fixed, 95% CI) -1.13 [-1.24, -1.02]
26 White blood cells 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
26.1 White blood cells (10
9/L) at 2 years
1 Mean Difference (IV, Fixed, 95% CI) -2.30 [-2.97, -1.63]
27 Dense cells 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
27.1 Dense cells (%) at 2 years 1 Mean Difference (IV, Fixed, 95% CI) -2.0 [-3.48, -0.52]
28 Leucocytes 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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28.1 Leucocytes (10³/mm³) at
18 months
1 Mean Difference (IV, Fixed, 95% CI) -0.84 [-3.07, 1.39]
29 Creatinine 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
29.1 Creatinine (mg/dL) at 2
years
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.11, 0.11]
30 Aspartate aminotransferase 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
30.1 Aspartate
aminotransferase at 2 years
1 Mean Difference (IV, Fixed, 95% CI) -4.0 [-9.40, 1.40]
31 Alkaline phosphatase 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
31.1 Alkaline phosphatase at
2 years
1 Mean Difference (IV, Fixed, 95% CI) -2.0 [-15.78, 11.78]
32 Change from baseline in
growth
1 Mean Difference (Fixed, 95% CI) Totals not selected
32.1 Height (cm) 1 Mean Difference (Fixed, 95% CI) -0.2 [1.00, 0.60]
32.2 Weight (kg) 1 Mean Difference (Fixed, 95% CI) 0.10 [-0.20, 0.40]
32.3 Head circumference (cm) 1 Mean Difference (Fixed, 95% CI) -0.2 [-0.60, 0.20]
33 Quality of life: general health
perception
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
33.1 General health
perception at 6 months
1 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.54, 1.14]
33.2 General health
perception at 1 year
1 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.18, 1.38]
33.3 General health
perception at 18 months
1 Mean Difference (IV, Fixed, 95% CI) 0.9 [0.08, 1.72]
33.4 General health
perception at 2 years
1 Mean Difference (IV, Fixed, 95% CI) 0.4 [-0.51, 1.31]
34 Quality of life: pain recall 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
34.1 Pain recall at 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.13, 0.93]
34.2 Pain recall at 1 year 1 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.18, 0.98]
34.3 Pain recall at 18 months 1 Mean Difference (IV, Fixed, 95% CI) 0.70 [0.11, 1.29]
34.4 Pain recall at 2 years 1 Mean Difference (IV, Fixed, 95% CI) 0.3 [-0.30, 0.90]
35 Quality of life: social function 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
35.1 Social function at 6
months
1 Mean Difference (IV, Fixed, 95% CI) 0.4 [-0.15, 0.95]
35.2 Social function at 1 year 1 Mean Difference (IV, Fixed, 95% CI) 0.2 [-0.36, 0.76]
35.3 Social function at 18
months
1 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.21, 1.01]
35.4 Social function at 2 years 1 Mean Difference (IV, Fixed, 95% CI) 0.3 [-0.31, 0.91]
36 Changes in ’Ladder of Life’ 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
36.1 Changes in ’Ladder of
Life’ at 6 months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.52, 0.52]
36.2 Changes in ’Ladder of
Life’ at 1 year
1 Mean Difference (IV, Fixed, 95% CI) 0.4 [-0.15, 0.95]
36.3 Changes in ’Ladder of
Life’ at 18 months
1 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.22, 0.82]
36.4 Changes in ’Ladder of
Life’ at 2 years
1 Mean Difference (IV, Fixed, 95% CI) 0.3 [-0.23, 0.83]
37 Proportion of participants with
signs of organ damage
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
37.1 New leg ulcers 1 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.44, 1.64]
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37.2 Aseptic necrosis
(humerus or femur)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.39, 2.37]
37.3 Decreased spleen
function at exit (compared to
baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.44, 1.16]
38 Signs of organ damage - change
from baseline in DTPA GFR
1 Mean Difference (Fixed, 95% CI) Totals not selected
39 Signs of organ damage - change
from baseline in Howell-Jolley
body (per 106 red blood cells)
1 Mean Difference (Fixed, 95% CI) Totals not selected
40 Signs of organ damage - change
from baseline in pitted cells
(%)
1 Mean Difference (Fixed, 95% CI) Totals not selected
41 Signs of organ damage - change
from baseline in spleen: liver
ratio of counts
1 Mean Difference (Fixed, 95% CI) Totals not selected
42 Signs of organ damage - change
from baseline in spleen volume
(cm3)
1 Mean Difference (Fixed, 95% CI) Totals not selected
43 Signs of organ damage - change
from baseline in creatinine
(mg/L)
1 Mean Difference (Fixed, 95% CI) Totals not selected
44 Signs of organ damage - change
from baseline in Schwartz GFR
1 Mean Difference (Fixed, 95% CI) Totals not selected
44.1 Schwartz glomerular
filtration rate (mL/min per
1.73m2)
1 Mean Difference (Fixed, 95% CI) -8.0 [-35.00, 21.00]
45 Signs of organ damage - change
from baseline in cystatin C
1 Mean Difference (Fixed, 95% CI) Totals not selected
46 Signs of organ damage -
change from baseline in urine
osmolality
1 Mean Difference (Fixed, 95% CI) Totals not selected
47 Signs of organ damage - change
from baseline in urine pH
1 Mean Difference (Fixed, 95% CI) Totals not selected
48 Signs of organ damage - change
from baseline in urine-specific
gravity
1 Mean Difference (Fixed, 95% CI) Totals not selected
49 Signs of organ damage - change
from baseline in total kidney
volume
1 Mean Difference (Fixed, 95% CI) Totals not selected
50 Signs of organ damage -
change from baseline in
TCD ultrasound velocity
(time-averagedmeanmaximum
velocity)
1 Mean Difference (Fixed, 95% CI) Totals not selected
51 Signs of organ damage - change
from baseline in CNS measures
1 Mean Difference (Fixed, 95% CI) Totals not selected
51.1 Bayley Mental
Development Index
1 Mean Difference (Fixed, 95% CI) 3.0 [0.00, 8.00]
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51.2 Bayley motor
performance development
index
1 Mean Difference (Fixed, 95% CI) 2.0 [-1.00, 7.00]
52 Proportion of participants
experiencing adverse events and
toxicity
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
52.1 hair loss at 1 or 2 visits 1 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.69, 2.26]
52.2 hair loss at 3 or more
visits
1 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.31, 1.21]
52.3 skin rash at 1 or 2 visits 1 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.62, 1.51]
52.4 skin rash at 3 or more
visits
1 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.58, 1.60]
52.5 fever at 1 or 2 visits 1 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.55, 1.69]
52.6 fever at 3 or more visits 1 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.68, 1.17]
52.7 Gastroinestinal
disturbance at 1 or 2 visits
1 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.50, 1.36]
52.8 Gastrointestinal
disturbance at 3 or more visits
1 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.31]
52.9 Other abnormalities at 1
or 2 visits
1 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.33, 1.11]
52.10 Other abnormalities at
3 or more visits
1 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.83, 1.40]
52.11 Hospitalisation (for any
reason)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.72, 0.96]
52.12 Dactylitis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.20, 0.58]
52.13 Priapism 1 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [0.26, 8.87]
52.14 Sepsis or bacteraemia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.08, 2.03]
52.15 Splenomegaly 1 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.61, 1.32]
52.16 Absolute Neutrophil
Count < 500
1 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [0.50, 12.71]
52.17 Absolute Neutrophil
500 - 1250
1 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.58, 4.03]
52.18 Thrombocytopaenia 1 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.64, 3.92]
52.19 Alanine transaminase >
150 U/L
1 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [0.19, 21.92]
52.20 Severe anaemia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.48]
52.21 Bilirubin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.17]
52.22 Creatinine 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
52.23 Skin and subcutaneous
disorders
1 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.75, 1.10]
52.24 Splenic sequestration 1 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.36, 2.23]
52.25 Gastroenteritis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.28, 0.71]
52.26 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.25, 99.95]
52.27 Skin Rash 1 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.38, 129.93]
62Hydroxyurea (hydroxycarbamide) for sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 2. Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD
and risk of stroke
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion experiencing pain 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Vaso-occlusive or sickle
cell-related pain (all)
1 133 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.81, 1.30]
1.2 Vaso-occlusive or sickle
cell-related pain (serious)
2 254 Risk Ratio (M-H, Fixed, 95% CI) 3.37 [1.59, 7.11]
2 Proportion experiencing
life-threatening events during
study
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Stroke (secondary) 1 133 Risk Ratio (M-H, Fixed, 95% CI) 14.78 [0.86, 253.66]
2.2 Transient ischaemic attack
(primary)
1 121 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.21, 4.84]
2.3 Transient ischaemic attack
(secondary)
1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.25, 1.74]
2.4 Other neurological event
(primary)
1 121 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.07, 15.88]
2.5 Acute chest syndrome 2 254 Risk Ratio (M-H, Fixed, 95% CI) 2.84 [1.25, 6.42]
2.6 Infections and Infestations 2 254 Risk Ratio (M-H, Fixed, 95% CI) 3.65 [1.05, 12.76]
2.7 Splenic sequestration or
splenectomy
2 254 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.16]
2.8 Hepatobiliary disease 1 121 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.07, 15.88]
2.9 Total with serious adverse
events
2 254 Risk Ratio (M-H, Fixed, 95% CI) 1.93 [1.17, 3.20]
2.10 Total with sickle cell
related, non-neurological
adverse events
1 133 Risk Ratio (M-H, Fixed, 95% CI) 3.10 [1.42, 6.75]
3 Deaths during the study 2 254 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.06, 15.42]
4 Change from baseline in fetal
haemoglobin (HbF %)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Change from baseline in absolute
neutrophil count (x10 /L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Change from baseline in mean
corpuscular volume (fL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Change from baseline in sickle
haemoglobin (%)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Change from baseline in
haemoglobin (g/L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9 Change from baseline in absolute
reticulocyte count (10 / L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10 Change from baseline in white
blood count (10 / L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11 Change from baseline in
platelets (10 / L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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12 Change from baseline in total
bilirubin (mg/L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13 Change from baseline in liver
iron concentration
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14 Change from baseline in serum
ferritin (ng/mL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15 Change from baseline in lactate
dehydrogenase (U/L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16 Signs of organ damage - CNS
measures at the end of the study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 Final TCD ultrasound
velocity
1 Mean Difference (IV, Fixed, 95% CI) -5.0 [-9.16, -0.84]
17 Proportion of participants
experiencing non-neurological
adverse events and toxicity
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
17.1 Infections and
infestations
1 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.89, 1.72]
17.2 Gastrointestinal disorders 1 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.74, 1.80]
17.3 Fever 1 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.66, 1.75]
17.4 Musculoskelatal
disorders
1 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.59, 2.20]
17.5 Immune system disorders 1 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.96]
17.6 Cholelithiasis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.17, 3.17]
17.7 Cholecystitis 1 Risk Ratio (M-H, Fixed, 95% CI) 1.97 [0.18, 21.21]
17.8 Asthma 1 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.17, 3.17]
17.9 Acute chest syndrome 1 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.53, 5.61]
17.10 Renal or urinary
disorder
1 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.11, 3.80]
17.11 Priapism 1 Risk Ratio (M-H, Fixed, 95% CI) 1.97 [0.18, 21.21]
17.12 Cathether-related
complications
1 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.26, 8.56]
17.13 Cardiac disorder 1 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.06, 15.42]
17.14 Hyderbilirubianemia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.24, 1.02]
17.15 Alanine transaminase
increase
1 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.55, 2.01]
17.16 Aspartate transaminase
increase
1 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.66, 2.88]
17.17 Serum creatinine
increase
1 Risk Ratio (M-H, Fixed, 95% CI) 1.97 [0.51, 7.55]
17.18 Thrombocytopenia 1 Risk Ratio (M-H, Fixed, 95% CI) 6.90 [0.87, 54.51]
17.19 Reticuloctopenia 1 Risk Ratio (M-H, Fixed, 95% CI) 6.90 [2.16, 22.02]
17.20 Neutropenia 1 Risk Ratio (M-H, Fixed, 95% CI) 9.85 [1.30, 74.80]
17.21 Anaemia 1 Risk Ratio (M-H, Fixed, 95% CI) 6.57 [2.05, 21.05]
17.22 Sickle cell pain 1 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.92, 1.82]
17.23 Sickle cell-related events 1 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.81, 1.30]
17.24 All adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.92, 1.05]
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Comparison 3. Hydroxyurea compared to observation for participants with SCD and risk of stroke
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion experiencing
life-threatening events during
the study
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Vaso-occlusive events 1 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.10, 1.64]
1.2 Acute splenic sequestration 1 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.05]
1.3 Blood transfusions
required
1 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.73]
2 Signs of organ damage -
proportion of participants with
a change in CNS measures
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Participants converting
from conditional to abnormal
TCD ultrasound velocity
1 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.03, 1.45]
3 Signs of organ damage - change
from baseline in CNS measures
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 TCD ultrasound
velocity (time-averaged mean
maximum velocity)
1 Mean Difference (IV, Fixed, 95% CI) -25.7 [-45.38, -6.02]
4 Adverse events and toxicity 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Dizziness 1 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.14, 66.53]
4.2 Headaches 1 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.05]
4.3 Transient neutropenia 1 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.14, 66.53]
4.4 Reticulocytopenia 1 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.05]
4.5 Parasite infection 1 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.05]
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Analysis 1.1. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 1
Pain crises.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 1 Pain crises
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean annual crisis rate at 2 years (all crises)
MSH 1995 152 5.1 (7.3) 147 7.9 (9.6) -2.80 [ -4.74, -0.86 ]
2 Mean annual crisis rate at 2 years (all crises requiring hospitalisation)
MSH 1995 152 2.4 (3.2) 147 3.9 (5.9) -1.50 [ -2.58, -0.42 ]
3 Number of vaso-occlusive crises after 18 months of treatment
Jain 2012 30 0.6 (1.37) 30 10.2 (3.24) -9.60 [ -10.86, -8.34 ]
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Analysis 1.2. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 2
Proportion experiencing pain.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 2 Proportion experiencing pain
Study or subgroup Hydroxyurea Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
BABY HUG 2011 37/96 55/97 0.68 [ 0.50, 0.92 ]
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Analysis 1.3. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 3
Proportion experiencing life threatening events during study.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 3 Proportion experiencing life threatening events during study
Study or subgroup Hydroxyurea Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Acute chest syndrome
BABY HUG 2011 7/96 18/97 25.7 % 0.39 [ 0.17, 0.90 ]
MSH 1995 23/152 51/147 74.3 % 0.44 [ 0.28, 0.68 ]
Subtotal (95% CI) 248 244 100.0 % 0.43 [ 0.29, 0.63 ]
Total events: 30 (Hydroxyurea), 69 (Placebo)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.33 (P = 0.000015)
2 Hepatic sequestration
MSH 1995 1/152 3/147 100.0 % 0.32 [ 0.03, 3.06 ]
Subtotal (95% CI) 152 147 100.0 % 0.32 [ 0.03, 3.06 ]
Total events: 1 (Hydroxyurea), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
3 Stroke
BABY HUG 2011 0/96 1/97 32.9 % 0.34 [ 0.01, 8.17 ]
MSH 1995 2/152 3/147 67.1 % 0.64 [ 0.11, 3.80 ]
Subtotal (95% CI) 248 244 100.0 % 0.54 [ 0.12, 2.53 ]
Total events: 2 (Hydroxyurea), 4 (Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
4 Patients transfused
BABY HUG 2011 20/96 33/97 29.0 % 0.61 [ 0.38, 0.99 ]
MSH 1995 55/152 79/147 71.0 % 0.67 [ 0.52, 0.87 ]
Subtotal (95% CI) 248 244 100.0 % 0.66 [ 0.52, 0.82 ]
Total events: 75 (Hydroxyurea), 112 (Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.60 (P = 0.00031)
5 Splenic sequestration
BABY HUG 2011 8/96 9/97 100.0 % 0.90 [ 0.36, 2.23 ]
Subtotal (95% CI) 96 97 100.0 % 0.90 [ 0.36, 2.23 ]
Total events: 8 (Hydroxyurea), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
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Analysis 1.4. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 4
Number of life-threatening events during study.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 4 Number of life-threatening events during study
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Blood transfusions
Jain 2012 30 0.13 (0.43) 30 1.98 (0.82) -1.85 [ -2.18, -1.52 ]
2 Hospitalisations
Jain 2012 30 0.7 (1.28) 30 9.59 (2.94) -8.89 [ -10.04, -7.74 ]
3 Duration of hospitalisation (days)
Jain 2012 30 3.1 (1.2) 30 7.1 (2.1) -4.00 [ -4.87, -3.13 ]
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Analysis 1.5. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 5
Deaths during the study.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 5 Deaths during the study
Study or subgroup Hydroxyurea Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All deaths
BABY HUG 2011 0/96 0/97 Not estimable
Jain 2012 0/30 0/30 Not estimable
MSH 1995 2/152 5/147 100.0 % 0.39 [ 0.08, 1.96 ]
Subtotal (95% CI) 278 274 100.0 % 0.39 [ 0.08, 1.96 ]
Total events: 2 (Hydroxyurea), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
2 Deaths related to SCD
BABY HUG 2011 0/96 0/97 Not estimable
Jain 2012 0/30 0/30 Not estimable
MSH 1995 2/152 4/147 100.0 % 0.48 [ 0.09, 2.60 ]
Subtotal (95% CI) 278 274 100.0 % 0.48 [ 0.09, 2.60 ]
Total events: 2 (Hydroxyurea), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
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Analysis 1.6. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 6
Change from baseline in fetal haemoglobin (HbF %).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 6 Change from baseline in fetal haemoglobin (HbF %)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 80 78 6.7 (0.994898) 6.70 [ 4.75, 8.65 ]
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Analysis 1.7. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 7
Fetal haemoglobin (HbF %) after treatment.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 7 Fetal haemoglobin (HbF %) after treatment
Study or subgroup Hydroxyurea Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jain 2012 30 24 (5.9) 30 18.92 (5.77) 14.3 % 5.08 [ 2.13, 8.03 ]
MSH 1995 152 8.6 (6.8) 147 4.7 (3.3) 85.7 % 3.90 [ 2.69, 5.11 ]
Total (95% CI) 182 177 100.0 % 4.07 [ 2.95, 5.18 ]
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 7.14 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 8
Change from baseline in absolute neutrophil count (x10³ per µL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 8 Change from baseline in absolute neutrophil count (x10 per L)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 69 72 -1.7 (0.612245) -1.70 [ -2.90, -0.50 ]
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Analysis 1.9. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 9
Neutrophil response (10 /L) after treatment.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 9 Neutrophil response (10 /L) after treatment
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Neutrophils (x10 9/l) at 10 weeks
MSH 1995 152 4.9 (2.6) 147 6.8 (2.8) -1.90 [ -2.51, -1.29 ]
2 Neutrophils (x10 9/l) at 2 years
MSH 1995 119 4.9 (2) 120 6.4 (2) -1.50 [ -2.01, -0.99 ]
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Analysis 1.10. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
10 Change from baseline in haemoglobin (g/L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 10 Change from baseline in haemoglobin (g/L)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 79 79 0.09 (0.020408) 0.09 [ 0.05, 0.13 ]
-0.5 -0.25 0 0.25 0.5
favours placebo favours hydroxyurea
Analysis 1.11. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
11 Change from baseline in m corpuscular volume (fL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 11 Change from baseline in m corpuscular volume (fL)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 79 79 5.7 (0.892857) 5.70 [ 3.95, 7.45 ]
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Analysis 1.12. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
12 Change from baseline in white blood cells (x10³ per µL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 12 Change from baseline in white blood cells (x10 per L)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 79 79 -3.4 (1.30102) -3.40 [ -5.95, -0.85 ]
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Analysis 1.13. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
13 Change from baseline in absolute reticulocyte count (x10³ per µL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 13 Change from baseline in absolute reticulocyte count (x10 per L)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 69 72 -71 (18.36735) -71.00 [ -107.00, -35.00 ]
-200 -100 0 100 200
Favours hydroxyurea Favours placebo
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Analysis 1.14. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
14 Change from baseline in reticulocytes (%).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 14 Change from baseline in reticulocytes (%)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 80 79 -3.1 (0.688776) -3.10 [ -4.45, -1.75 ]
-20 -10 0 10 20
Favours hydroxyurea Favours placebo
Analysis 1.15. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
15 Change from baseline in total bilirubin (mg/L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 15 Change from baseline in total bilirubin (mg/L)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 81 85 -0.5 (0.178571) -0.50 [ -0.85, -0.15 ]
-2 -1 0 1 2
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Analysis 1.16. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
16 Change from baseline in platelet count (x10³ per µL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 16 Change from baseline in platelet count (x10 per L)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 78 79 -33 (27.551) -33.00 [ -87.00, 21.00 ]
-200 -100 0 100 200
Favours hydroxyurea Favours placebo
Analysis 1.17. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
17 Haemoglobin (g/dL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 17 Haemoglobin (g/dL)
Study or subgroup Hydroxyurea Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 10 weeks
MSH 1995 152 9.1 (1.4) 147 8.6 (1.3) 100.0 % 0.50 [ 0.19, 0.81 ]
Subtotal (95% CI) 152 147 100.0 % 0.50 [ 0.19, 0.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.20 (P = 0.0014)
2 At the end of the study
Jain 2012 30 9.29 (0.55) 30 7.9 (0.58) 55.3 % 1.39 [ 1.10, 1.68 ]
MSH 1995 152 9.1 (1.5) 147 8.5 (1.3) 44.7 % 0.60 [ 0.28, 0.92 ]
Subtotal (95% CI) 182 177 100.0 % 1.04 [ 0.82, 1.25 ]
Heterogeneity: Chi2 = 13.11, df = 1 (P = 0.00029); I2 =92%
Test for overall effect: Z = 9.56 (P < 0.00001)
-2 -1 0 1 2
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Analysis 1.18. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
18 Mean corpuscular volume (fL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 18 Mean corpuscular volume (fL)
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 10 weeks
MSH 1995 152 104.9 (13.5) 147 92.6 (9.2) 12.30 [ 9.69, 14.91 ]
2 At 2 years
MSH 1995 152 103 (14) 147 93 (9) 10.00 [ 7.34, 12.66 ]
-20 -10 0 10 20
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Analysis 1.19. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
19 Total bilirubin (mg/L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 19 Total bilirubin (mg/L)
Study or subgroup Hydroxyurea Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At the end of the study
Jain 2012 30 1.1 (0.42) 30 2.71 (0.93) 84.2 % -1.61 [ -1.98, -1.24 ]
MSH 1995 152 2.9 (2.5) 147 4.2 (4.6) 15.8 % -1.30 [ -2.14, -0.46 ]
Subtotal (95% CI) 182 177 100.0 % -1.56 [ -1.90, -1.23 ]
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 9.13 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours hydroxyurea Favours placebo
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Analysis 1.20. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
20 Reticulocytes.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 20 Reticulocytes
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Reticulocytes (10 /mm ) at 18 months
Jain 2012 30 1.15 (0.1) 30 1.81 (0.67) -0.66 [ -0.90, -0.42 ]
2 Reticulocytes (10 /L) at 10 weeks
MSH 1995 152 194 (86) 147 324 (108) -130.00 [ -152.17, -107.83 ]
3 Reticulocytes (10 /L) at 2 years
MSH 1995 152 231 (100) 147 300 (99) -69.00 [ -91.56, -46.44 ]
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Analysis 1.21. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
21 Platelet count.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 21 Platelet count
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Platelet count (10 /mm ) at 18 months
Jain 2012 30 2.01 (0.18) 30 2.06 (0.26) -0.05 [ -0.16, 0.06 ]
2 Platelet count (x10 /L) at 10 weeks
MSH 1995 152 434 (190) 147 469 (164) -35.00 [ -75.19, 5.19 ]
3 Platelet count (x10 /L) at 2 years
MSH 1995 152 399 (124) 147 423 (122) -24.00 [ -51.88, 3.88 ]
-50 -25 0 25 50
Favours hydroxyurea Favours placebo
Analysis 1.22. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
22 Packed cell volume.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 22 Packed cell volume
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Packed cell volume (%) at 2 years
MSH 1995 152 27 (5) 147 25.1 (4.2) 1.90 [ 0.85, 2.95 ]
-4 -2 0 2 4
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Analysis 1.23. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
23 F reticulocytes.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 23 F reticulocytes
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 F reticulocytes at 2 years
MSH 1995 152 17 (9) 147 15 (7) 2.00 [ 0.18, 3.82 ]
-4 -2 0 2 4
Favours placebo Favours hydroxyurea
Analysis 1.24. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
24 F cells.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 24 F cells
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 F cells (%) at 2 years
MSH 1995 152 48 (23) 147 35 (18) 13.00 [ 8.33, 17.67 ]
-100 -50 0 50 100
Favours placebo Favours hydroxyurea
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Analysis 1.25. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
25 Red blood count.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 25 Red blood count
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Red blood count (10 /mm ) at 18 months
Jain 2012 30 1.98 (0.22) 30 3.11 (0.2) -1.13 [ -1.24, -1.02 ]
-1 -0.5 0 0.5 1
Favours hydroxyurea Favours placebo
Analysis 1.26. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
26 White blood cells.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 26 White blood cells
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 White blood cells (10
9
/L) at 2 years
MSH 1995 152 9.9 (3.1) 147 12.2 (2.8) -2.30 [ -2.97, -1.63 ]
-10 -5 0 5 10
Favours hydroxyurea Favours placebo
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Analysis 1.27. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
27 Dense cells.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 27 Dense cells
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Dense cells (%) at 2 years
MSH 1995 152 11 (6) 147 13 (7) -2.00 [ -3.48, -0.52 ]
-4 -2 0 2 4
Favours hydroxyurea Favours placebo
Analysis 1.28. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
28 Leucocytes.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 28 Leucocytes
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Leucocytes (10 /mm ) at 18 months
Jain 2012 30 6.54 (5.54) 30 7.38 (2.85) -0.84 [ -3.07, 1.39 ]
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Analysis 1.29. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
29 Creatinine.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 29 Creatinine
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Creatinine (mg/dL) at 2 years
MSH 1995 152 1 (0.5) 147 1 (0.5) 0.0 [ -0.11, 0.11 ]
-0.5 -0.25 0 0.25 0.5
Favours hydroxyurea Favours placebo
Analysis 1.30. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
30 Aspartate aminotransferase.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 30 Aspartate aminotransferase
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Aspartate aminotransferase at 2 years
MSH 1995 152 39 (20) 147 43 (27) -4.00 [ -9.40, 1.40 ]
-20 -10 0 10 20
Favours hydroxyurea Favours placebo
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Analysis 1.31. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
31 Alkaline phosphatase.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 31 Alkaline phosphatase
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Alkaline phosphatase at 2 years
MSH 1995 152 117 (48) 147 119 (71) -2.00 [ -15.78, 11.78 ]
-100 -50 0 50 100
Favours hydroxyurea Favours placebo
Analysis 1.32. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
32 Change from baseline in growth.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 32 Change from baseline in growth
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Height (cm)
BABY HUG 2011 87 82 -0.2 (0.408163) -0.20 [ -1.00, 0.60 ]
2 Weight (kg)
BABY HUG 2011 87 82 0.1 (0.153061) 0.10 [ -0.20, 0.40 ]
3 Head circumference (cm)
BABY HUG 2011 85 82 -0.2 (0.204082) -0.20 [ -0.60, 0.20 ]
-1 -0.5 0 0.5 1
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Analysis 1.33. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
33 Quality of life: general health perception.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 33 Quality of life: general health perception
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General health perception at 6 months
MSH 1995 148 1.3 (3.7) 137 1 (3.5) 0.30 [ -0.54, 1.14 ]
2 General health perception at 1 year
MSH 1995 146 1.6 (3.3) 138 1 (3.4) 0.60 [ -0.18, 1.38 ]
3 General health perception at 18 months
MSH 1995 144 1.5 (3.6) 136 0.6 (3.4) 0.90 [ 0.08, 1.72 ]
4 General health perception at 2 years
MSH 1995 141 1.3 (4.1) 136 0.9 (3.6) 0.40 [ -0.51, 1.31 ]
-2 -1 0 1 2
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Analysis 1.34. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
34 Quality of life: pain recall.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 34 Quality of life: pain recall
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pain recall at 6 months
MSH 1995 148 0.6 (2.4) 137 0.2 (2.2) 0.40 [ -0.13, 0.93 ]
2 Pain recall at 1 year
MSH 1995 146 0.7 (2.6) 138 0.3 (2.4) 0.40 [ -0.18, 0.98 ]
3 Pain recall at 18 months
MSH 1995 144 0.8 (2.5) 136 0.1 (2.5) 0.70 [ 0.11, 1.29 ]
4 Pain recall at 2 years
MSH 1995 141 0.6 (2.7) 136 0.3 (2.4) 0.30 [ -0.30, 0.90 ]
-1 -0.5 0 0.5 1
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Analysis 1.35. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
35 Quality of life: social function.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 35 Quality of life: social function
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Social function at 6 months
MSH 1995 148 0.5 (2.3) 137 0.1 (2.4) 0.40 [ -0.15, 0.95 ]
2 Social function at 1 year
MSH 1995 146 0.4 (2.3) 138 0.2 (2.5) 0.20 [ -0.36, 0.76 ]
3 Social function at 18 months
MSH 1995 144 0.6 (2.5) 136 0.2 (2.7) 0.40 [ -0.21, 1.01 ]
4 Social function at 2 years
MSH 1995 141 0.6 (2.7) 136 0.3 (2.5) 0.30 [ -0.31, 0.91 ]
-1 -0.5 0 0.5 1
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Analysis 1.36. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
36 Changes in ’Ladder of Life’.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 36 Changes in ’Ladder of Life’
Study or subgroup Hydroxyurea Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Changes in ’Ladder of Life’ at 6 months
MSH 1995 148 -0.2 (2.2) 137 -0.2 (2.3) 0.0 [ -0.52, 0.52 ]
2 Changes in ’Ladder of Life’ at 1 year
MSH 1995 146 -0.1 (2.4) 138 -0.5 (2.3) 0.40 [ -0.15, 0.95 ]
3 Changes in ’Ladder of Life’ at 18 months
MSH 1995 144 -0.1 (2.3) 136 -0.4 (2.1) 0.30 [ -0.22, 0.82 ]
4 Changes in ’Ladder of Life’ at 2 years
MSH 1995 141 -0.1 (2.3) 136 -0.4 (2.2) 0.30 [ -0.23, 0.83 ]
-1 -0.5 0 0.5 1
Favours Placebo Favours Hydroxyurea
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Analysis 1.37. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
37 Proportion of participants with signs of organ damage.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 37 Proportion of participants with signs of organ damage
Study or subgroup Hydroxyurea Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 New leg ulcers
MSH 1995 15/152 17/147 0.85 [ 0.44, 1.64 ]
2 Aseptic necrosis (humerus or femur)
MSH 1995 9/152 9/147 0.97 [ 0.39, 2.37 ]
3 Decreased spleen function at exit (compared to baseline)
BABY HUG 2011 19/70 28/74 0.72 [ 0.44, 1.16 ]
0.2 0.5 1 2 5
Favours hydroxyurea Favours placebo
Analysis 1.38. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
38 Signs of organ damage - change from baseline in DTPA GFR.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 38 Signs of organ damage - change from baseline in DTPA GFR
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 67 66 2 (9.183673) 2.00 [ -16.00, 20.00 ]
-100 -50 0 50 100
Favours hydroxyurea Favours placebo
89Hydroxyurea (hydroxycarbamide) for sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.39. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
39 Signs of organ damage - change from baseline in Howell-Jolley body (per 106 red blood cells).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 39 Signs of organ damage - change from baseline in Howell-Jolley body (per 10
6
red blood cells)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 76 82 -274 (134.69387) -274.00 [ -538.00, -10.00 ]
-500 -250 0 250 500
Favours hydroxyurea Favours placebo
Analysis 1.40. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
40 Signs of organ damage - change from baseline in pitted cells (%).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 40 Signs of organ damage - change from baseline in pitted cells (%)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 85 82 -2.5 (1.147959) -2.50 [ -4.75, -0.25 ]
-4 -2 0 2 4
Favours hydroxyurea Favours placebo
90Hydroxyurea (hydroxycarbamide) for sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.41. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
41 Signs of organ damage - change from baseline in spleen: liver ratio of counts.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 41 Signs of organ damage - change from baseline in spleen: liver ratio of counts
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 84 79 0.1 (0.045918) 0.10 [ 0.01, 0.19 ]
-0.5 -0.25 0 0.25 0.5
Favours placebo Favours hydroxyurea
Analysis 1.42. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
42 Signs of organ damage - change from baseline in spleen volume (cm3).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 42 Signs of organ damage - change from baseline in spleen volume (cm
3
)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 80 80 14 (14.28571) 14.00 [ -14.00, 42.00 ]
-100 -50 0 50 100
Favours placebo Favours hydroxyurea
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Analysis 1.43. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
43 Signs of organ damage - change from baseline in creatinine (mg/L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 43 Signs of organ damage - change from baseline in creatinine (mg/L)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 69 78 -0.05 (0.017857) -0.05 [ -0.08, -0.02 ]
-0.1 -0.05 0 0.05 0.1
Favours hydroxyurea Favours placebo
Analysis 1.44. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
44 Signs of organ damage - change from baseline in Schwartz GFR.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 44 Signs of organ damage - change from baseline in Schwartz GFR
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Schwartz glomerular filtration rate (mL/min per 1.73m
2
)
BABY HUG 2011 69 73 -8 (14.79592) -8.00 [ -37.00, 21.00 ]
-100 -50 0 50 100
Favours hydroxyurea Favours placebo
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Analysis 1.45. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
45 Signs of organ damage - change from baseline in cystatin C.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 45 Signs of organ damage - change from baseline in cystatin C
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 39 48 0.03 (0.04082) 0.03 [ -0.05, 0.11 ]
-0.2 -0.1 0 0.1 0.2
Favours hydroxyurea Favours placebo
Analysis 1.46. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
46 Signs of organ damage - change from baseline in urine osmolality.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 46 Signs of organ damage - change from baseline in urine osmolality
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 81 84 57 (27.29592) 57.00 [ 3.50, 110.50 ]
-100 -50 0 50 100
Favours placebo Favours hydroxyurea
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Analysis 1.47. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
47 Signs of organ damage - change from baseline in urine pH.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 47 Signs of organ damage - change from baseline in urine pH
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 86 82 0.15 (0.18622449) 0.15 [ -0.21, 0.51 ]
-1 -0.5 0 0.5 1
Favours placebo Favours hydroxyurea
Analysis 1.48. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
48 Signs of organ damage - change from baseline in urine-specific gravity.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 48 Signs of organ damage - change from baseline in urine-specific gravity
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 86 82 0.002 (0.000918) 0.00 [ 0.00, 0.00 ]
-0.01 -0.01 0 0.01 0.01
Favours placebo Favours hydroxyurea
94Hydroxyurea (hydroxycarbamide) for sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.49. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
49 Signs of organ damage - change from baseline in total kidney volume.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 49 Signs of organ damage - change from baseline in total kidney volume
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 86 79 -9 (3.571429) -9.00 [ -16.00, -2.00 ]
-100 -50 0 50 100
Favours hydroxyurea Favours placebo
Analysis 1.50. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
50 Signs of organ damage - change from baseline in TCD ultrasound velocity (time-averaged mean maximum
velocity).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 50 Signs of organ damage - change from baseline in TCD ultrasound velocity (time-averaged mean maximum velocity)
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
BABY HUG 2011 79 79 -12 (3.061224) -12.00 [ -18.00, -6.00 ]
-100 -50 0 50 100
Favours hydroxyurea Favours placebo
95Hydroxyurea (hydroxycarbamide) for sickle cell disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.51. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
51 Signs of organ damage - change from baseline in CNS measures.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 51 Signs of organ damage - change from baseline in CNS measures
Study or subgroup Hydroxyurea Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Bayley Mental Development Index
BABY HUG 2011 85 80 3 (2.55102) 3.00 [ -2.00, 8.00 ]
2 Bayley motor performance development index
BABY HUG 2011 85 79 2 (2.55102) 2.00 [ -3.00, 7.00 ]
-100 -50 0 50 100
Favours placebo Favours hydroxyurea
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Analysis 1.52. Comparison 1 Hydroxyurea versus placebo for participants with sickle cell disease, Outcome
52 Proportion of participants experiencing adverse events and toxicity.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 1 Hydroxyurea versus placebo for participants with sickle cell disease
Outcome: 52 Proportion of participants experiencing adverse events and toxicity
Study or subgroup Hydroxyurea Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 hair loss at 1 or 2 visits
MSH 1995 22/152 17/147 1.25 [ 0.69, 2.26 ]
2 hair loss at 3 or more visits
MSH 1995 12/152 19/147 0.61 [ 0.31, 1.21 ]
3 skin rash at 1 or 2 visits
MSH 1995 31/152 31/147 0.97 [ 0.62, 1.51 ]
4 skin rash at 3 or more visits
MSH 1995 25/152 25/147 0.97 [ 0.58, 1.60 ]
5 fever at 1 or 2 visits
MSH 1995 21/152 21/147 0.97 [ 0.55, 1.69 ]
6 fever at 3 or more visits
MSH 1995 60/152 65/147 0.89 [ 0.68, 1.17 ]
7 Gastroinestinal disturbance at 1 or 2 visits
MSH 1995 24/152 28/147 0.83 [ 0.50, 1.36 ]
8 Gastrointestinal disturbance at 3 or more visits
MSH 1995 59/152 58/147 0.98 [ 0.74, 1.31 ]
9 Other abnormalities at 1 or 2 visits
MSH 1995 15/152 24/147 0.60 [ 0.33, 1.11 ]
10 Other abnormalities at 3 or more visits
MSH 1995 68/152 61/147 1.08 [ 0.83, 1.40 ]
11 Hospitalisation (for any reason)
BABY HUG 2011 69/96 84/97 0.83 [ 0.72, 0.96 ]
12 Dactylitis
BABY HUG 2011 14/96 42/97 0.34 [ 0.20, 0.58 ]
13 Priapism
BABY HUG 2011 3/96 2/97 1.52 [ 0.26, 8.87 ]
14 Sepsis or bacteraemia
BABY HUG 2011 2/96 5/97 0.40 [ 0.08, 2.03 ]
15 Splenomegaly
0.2 0.5 1 2 5
Favours hydroxycarbamide Favours placebo
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(. . . Continued)
Study or subgroup Hydroxyurea Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
BABY HUG 2011 32/96 36/97 0.90 [ 0.61, 1.32 ]
16 Absolute Neutrophil Count < 500
BABY HUG 2011 5/96 2/97 2.53 [ 0.50, 12.71 ]
17 Absolute Neutrophil 500 - 1250
BABY HUG 2011 45/96 18/97 2.53 [ 1.58, 4.03 ]
18 Thrombocytopaenia
BABY HUG 2011 11/96 7/97 1.59 [ 0.64, 3.92 ]
19 Alanine transaminase > 150 U/L
BABY HUG 2011 2/96 1/97 2.02 [ 0.19, 21.92 ]
20 Severe anaemia
BABY HUG 2011 1/96 2/97 0.51 [ 0.05, 5.48 ]
21 Bilirubin
BABY HUG 2011 0/96 1/97 0.34 [ 0.01, 8.17 ]
22 Creatinine
BABY HUG 2011 0/96 0/97 Not estimable
23 Skin and subcutaneous disorders
BABY HUG 2011 62/96 69/97 0.91 [ 0.75, 1.10 ]
24 Splenic sequestration
BABY HUG 2011 8/96 9/97 0.90 [ 0.36, 2.23 ]
25 Gastroenteritis
BABY HUG 2011 18/96 41/97 0.44 [ 0.28, 0.71 ]
26 Nausea
Jain 2012 2/30 0/30 5.00 [ 0.25, 99.95 ]
27 Skin Rash
Jain 2012 3/30 0/30 7.00 [ 0.38, 129.93 ]
0.2 0.5 1 2 5
Favours hydroxycarbamide Favours placebo
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Analysis 2.1. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 1 Proportion experiencing pain.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 1 Proportion experiencing pain
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaso-occlusive or sickle cell-related pain (all)
SWiTCH 2012 46/67 44/66 100.0 % 1.03 [ 0.81, 1.30 ]
Subtotal (95% CI) 67 66 100.0 % 1.03 [ 0.81, 1.30 ]
Total events: 46 (Hydroxyurea / Phlebotomy), 44 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
2 Vaso-occlusive or sickle cell-related pain (serious)
SWiTCH 2012 16/67 5/66 62.9 % 3.15 [ 1.23, 8.11 ]
TWiTCH 2016 11/60 3/61 37.1 % 3.73 [ 1.09, 12.70 ]
Subtotal (95% CI) 127 127 100.0 % 3.37 [ 1.59, 7.11 ]
Total events: 27 (Hydroxyurea / Phlebotomy), 8 (Transfusion / Chelation)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
0.01 0.1 1 10 100
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Analysis 2.2. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 2 Proportion experiencing life-threatening events during
study.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 2 Proportion experiencing life-threatening events during study
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Stroke (secondary)
SWiTCH 2012 7/67 0/66 100.0 % 14.78 [ 0.86, 253.66 ]
Subtotal (95% CI) 67 66 100.0 % 14.78 [ 0.86, 253.66 ]
Total events: 7 (Hydroxyurea / Phlebotomy), 0 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
2 Transient ischaemic attack (primary)
TWiTCH 2016 3/60 3/61 100.0 % 1.02 [ 0.21, 4.84 ]
Subtotal (95% CI) 60 61 100.0 % 1.02 [ 0.21, 4.84 ]
Total events: 3 (Hydroxyurea / Phlebotomy), 3 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
3 Transient ischaemic attack (secondary)
SWiTCH 2012 6/67 9/66 100.0 % 0.66 [ 0.25, 1.74 ]
Subtotal (95% CI) 67 66 100.0 % 0.66 [ 0.25, 1.74 ]
Total events: 6 (Hydroxyurea / Phlebotomy), 9 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
4 Other neurological event (primary)
TWiTCH 2016 1/60 1/61 100.0 % 1.02 [ 0.07, 15.88 ]
Subtotal (95% CI) 60 61 100.0 % 1.02 [ 0.07, 15.88 ]
Total events: 1 (Hydroxyurea / Phlebotomy), 1 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
5 Acute chest syndrome
SWiTCH 2012 16/67 5/66 71.7 % 3.15 [ 1.23, 8.11 ]
TWiTCH 2016 4/60 2/61 28.3 % 2.03 [ 0.39, 10.69 ]
Subtotal (95% CI) 127 127 100.0 % 2.84 [ 1.25, 6.42 ]
Total events: 20 (Hydroxyurea / Phlebotomy), 7 (Transfusion / Chelation)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
0.005 0.1 1 10 200
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
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(. . . Continued)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Infections and Infestations
SWiTCH 2012 7/67 2/66 67.0 % 3.45 [ 0.74, 15.99 ]
TWiTCH 2016 4/60 1/61 33.0 % 4.07 [ 0.47, 35.34 ]
Subtotal (95% CI) 127 127 100.0 % 3.65 [ 1.05, 12.76 ]
Total events: 11 (Hydroxyurea / Phlebotomy), 3 (Transfusion / Chelation)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
7 Splenic sequestration or splenectomy
SWiTCH 2012 0/67 0/66 Not estimable
TWiTCH 2016 0/60 1/61 100.0 % 0.34 [ 0.01, 8.16 ]
Subtotal (95% CI) 127 127 100.0 % 0.34 [ 0.01, 8.16 ]
Total events: 0 (Hydroxyurea / Phlebotomy), 1 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
8 Hepatobiliary disease
TWiTCH 2016 1/60 1/61 100.0 % 1.02 [ 0.07, 15.88 ]
Subtotal (95% CI) 60 61 100.0 % 1.02 [ 0.07, 15.88 ]
Total events: 1 (Hydroxyurea / Phlebotomy), 1 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
9 Total with serious adverse events
SWiTCH 2012 26/67 12/66 67.0 % 2.13 [ 1.18, 3.86 ]
TWiTCH 2016 9/60 6/61 33.0 % 1.53 [ 0.58, 4.02 ]
Subtotal (95% CI) 127 127 100.0 % 1.93 [ 1.17, 3.20 ]
Total events: 35 (Hydroxyurea / Phlebotomy), 18 (Transfusion / Chelation)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.011)
10 Total with sickle cell related, non-neurological adverse events
SWiTCH 2012 22/67 7/66 100.0 % 3.10 [ 1.42, 6.75 ]
Subtotal (95% CI) 67 66 100.0 % 3.10 [ 1.42, 6.75 ]
Total events: 22 (Hydroxyurea / Phlebotomy), 7 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0045)
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Analysis 2.3. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 3 Deaths during the study.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 3 Deaths during the study
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SWiTCH 2012 1/67 1/66 100.0 % 0.99 [ 0.06, 15.42 ]
TWiTCH 2016 0/60 0/61 Not estimable
Total (95% CI) 127 127 100.0 % 0.99 [ 0.06, 15.42 ]
Total events: 1 (Hydroxyurea / Phlebotomy), 1 (Transfusion / Chelation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
Analysis 2.4. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 4 Change from baseline in fetal haemoglobin (HbF %).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 4 Change from baseline in fetal haemoglobin (HbF %)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 15.5 (7.1) 61 -0.1 (5) 15.60 [ 13.41, 17.79 ]
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Analysis 2.5. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 5 Change from baseline in absolute neutrophil count
(x10 /L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 5 Change from baseline in absolute neutrophil count (x10 /L)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -4.4 (3.2) 61 0 (2.6) -4.40 [ -5.44, -3.36 ]
-10 -5 0 5 10
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Analysis 2.6. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 6 Change from baseline in mean corpuscular volume (fL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 6 Change from baseline in mean corpuscular volume (fL)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 21 (10) 61 0 (4) 21.00 [ 18.28, 23.72 ]
-20 -10 0 10 20
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Analysis 2.7. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 7 Change from baseline in sickle haemoglobin (%).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 7 Change from baseline in sickle haemoglobin (%)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 43 (15.5) 61 1.2 (10.7) 41.80 [ 37.05, 46.55 ]
-50 -25 0 25 50
Favours Transfusion / Chelation Favours Hydroxyurea / Phlebotomy
Analysis 2.8. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 8 Change from baseline in haemoglobin (g/L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 8 Change from baseline in haemoglobin (g/L)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -2 (12) 61 8.7 (10) -10.70 [ -14.64, -6.76 ]
-100 -50 0 50 100
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
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Analysis 2.9. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 9 Change from baseline in absolute reticulocyte count
(10 / L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 9 Change from baseline in absolute reticulocyte count (10 / L)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -169 (157) 61 9 (158) -178.00 [ -234.13, -121.87 ]
-200 -100 0 100 200
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
Analysis 2.10. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 10 Change from baseline in white blood count (10 / L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 10 Change from baseline in white blood count (10 / L)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -6.6 (3.9) 61 -0.4 (2.9) -6.20 [ -7.43, -4.97 ]
-10 -5 0 5 10
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Analysis 2.11. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 11 Change from baseline in platelets (10 / L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 11 Change from baseline in platelets (10 / L)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -73 (135) 61 -3 (86) -70.00 [ -110.41, -29.59 ]
-200 -100 0 100 200
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
Analysis 2.12. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 12 Change from baseline in total bilirubin (mg/L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 12 Change from baseline in total bilirubin (mg/L)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -13.3 (12.7) 61 3.3 (9) -16.60 [ -20.53, -12.67 ]
-100 -50 0 50 100
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Analysis 2.13. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 13 Change from baseline in liver iron concentration.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 13 Change from baseline in liver iron concentration
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -1.9 (4.2) 61 2.4 (8.7) -4.30 [ -6.73, -1.87 ]
-20 -10 0 10 20
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
Analysis 2.14. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 14 Change from baseline in serum ferritin (ng/mL).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 14 Change from baseline in serum ferritin (ng/mL)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -1805 (1651) 61 -38 (2095) -1767.00 [ -2438.50, -1095.50 ]
-1000 -500 0 500 1000
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Analysis 2.15. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 15 Change from baseline in lactate dehydrogenase (U/L).
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 15 Change from baseline in lactate dehydrogenase (U/L)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
TWiTCH 2016 60 -140 (231) 61 -6 (215) -134.00 [ -213.55, -54.45 ]
-200 -100 0 100 200
favours Hydroxyurea / Phlebotomy favours Transfusion / Chelation
Analysis 2.16. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 16 Signs of organ damage - CNS measures at the end of
the study.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 16 Signs of organ damage - CNS measures at the end of the study
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Final TCD ultrasound velocity
TWiTCH 2016 60 138 (11.6132) 61 143 (11.7136) -5.00 [ -9.16, -0.84 ]
-20 -10 0 10 20
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
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Analysis 2.17. Comparison 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for
participants with SCD and risk of stroke, Outcome 17 Proportion of participants experiencing non-
neurological adverse events and toxicity.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 2 Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke
Outcome: 17 Proportion of participants experiencing non-neurological adverse events and toxicity
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Infections and infestations
SWiTCH 2012 39/67 31/66 1.24 [ 0.89, 1.72 ]
2 Gastrointestinal disorders
SWiTCH 2012 27/67 23/66 1.16 [ 0.74, 1.80 ]
3 Fever
SWiTCH 2012 23/67 21/66 1.08 [ 0.66, 1.75 ]
4 Musculoskelatal disorders
SWiTCH 2012 15/67 13/66 1.14 [ 0.59, 2.20 ]
5 Immune system disorders
SWiTCH 2012 1/67 8/66 0.12 [ 0.02, 0.96 ]
6 Cholelithiasis
SWiTCH 2012 3/67 4/66 0.74 [ 0.17, 3.17 ]
7 Cholecystitis
SWiTCH 2012 2/67 1/66 1.97 [ 0.18, 21.21 ]
8 Asthma
SWiTCH 2012 3/67 4/66 0.74 [ 0.17, 3.17 ]
9 Acute chest syndrome
SWiTCH 2012 7/67 4/66 1.72 [ 0.53, 5.61 ]
10 Renal or urinary disorder
SWiTCH 2012 2/67 3/66 0.66 [ 0.11, 3.80 ]
11 Priapism
SWiTCH 2012 2/67 1/66 1.97 [ 0.18, 21.21 ]
12 Cathether-related complications
SWiTCH 2012 3/67 2/66 1.48 [ 0.26, 8.56 ]
13 Cardiac disorder
SWiTCH 2012 1/67 1/66 0.99 [ 0.06, 15.42 ]
14 Hyderbilirubianemia
SWiTCH 2012 9/67 18/66 0.49 [ 0.24, 1.02 ]
0.02 0.1 1 10 50
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
(Continued . . . )
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(. . . Continued)
Study or subgroup
Hydroxyurea
/ Phlebotomy
Transfusion
/ Chelation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Alanine transaminase increase
SWiTCH 2012 15/67 14/66 1.06 [ 0.55, 2.01 ]
16 Aspartate transaminase increase
SWiTCH 2012 14/67 10/66 1.38 [ 0.66, 2.88 ]
17 Serum creatinine increase
SWiTCH 2012 6/67 3/66 1.97 [ 0.51, 7.55 ]
18 Thrombocytopenia
SWiTCH 2012 7/67 1/66 6.90 [ 0.87, 54.51 ]
19 Reticuloctopenia
SWiTCH 2012 21/67 3/66 6.90 [ 2.16, 22.02 ]
20 Neutropenia
SWiTCH 2012 10/67 1/66 9.85 [ 1.30, 74.80 ]
21 Anaemia
SWiTCH 2012 20/67 3/66 6.57 [ 2.05, 21.05 ]
22 Sickle cell pain
SWiTCH 2012 38/67 29/66 1.29 [ 0.92, 1.82 ]
23 Sickle cell-related events
SWiTCH 2012 46/67 44/66 1.03 [ 0.81, 1.30 ]
24 All adverse events
SWiTCH 2012 64/67 64/66 0.99 [ 0.92, 1.05 ]
0.02 0.1 1 10 50
Favours Hydroxyurea / Phlebotomy Favours Transfusion / Chelation
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Analysis 3.1. Comparison 3 Hydroxyurea compared to observation for participants with SCD and risk of
stroke, Outcome 1 Proportion experiencing life-threatening events during the study.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 3 Hydroxyurea compared to observation for participants with SCD and risk of stroke
Outcome: 1 Proportion experiencing life-threatening events during the study
Study or subgroup Hydroxyurea Observation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaso-occlusive events
SCATE 2015 2/11 5/11 0.40 [ 0.10, 1.64 ]
2 Acute splenic sequestration
SCATE 2015 1/11 1/11 1.00 [ 0.07, 14.05 ]
3 Blood transfusions required
SCATE 2015 1/11 3/11 0.33 [ 0.04, 2.73 ]
0.01 0.1 1 10 100
Favours hydroxyurea Favours observation
Analysis 3.2. Comparison 3 Hydroxyurea compared to observation for participants with SCD and risk of
stroke, Outcome 2 Signs of organ damage - proportion of participants with a change in CNS measures.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 3 Hydroxyurea compared to observation for participants with SCD and risk of stroke
Outcome: 2 Signs of organ damage - proportion of participants with a change in CNS measures
Study or subgroup Hydroxyurea Observation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants converting from conditional to abnormal TCD ultrasound velocity
SCATE 2015 1/11 5/11 0.20 [ 0.03, 1.45 ]
0.01 0.1 1 10 100
Favours hydroxyurea Favours observation
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Analysis 3.3. Comparison 3 Hydroxyurea compared to observation for participants with SCD and risk of
stroke, Outcome 3 Signs of organ damage - change from baseline in CNS measures.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 3 Hydroxyurea compared to observation for participants with SCD and risk of stroke
Outcome: 3 Signs of organ damage - change from baseline in CNS measures
Study or subgroup Hydroxyurea Observation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 TCD ultrasound velocity (time-averaged mean maximum velocity)
SCATE 2015 11 -15.5 (24.7094) 11 10.2 (22.3278) -25.70 [ -45.38, -6.02 ]
-100 -50 0 50 100
Favours hydroxyurea Favours observation
Analysis 3.4. Comparison 3 Hydroxyurea compared to observation for participants with SCD and risk of
stroke, Outcome 4 Adverse events and toxicity.
Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Comparison: 3 Hydroxyurea compared to observation for participants with SCD and risk of stroke
Outcome: 4 Adverse events and toxicity
Study or subgroup Favours hydroxyurea Observation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dizziness
SCATE 2015 1/11 0/11 3.00 [ 0.14, 66.53 ]
2 Headaches
SCATE 2015 1/11 1/11 1.00 [ 0.07, 14.05 ]
3 Transient neutropenia
SCATE 2015 1/11 0/11 3.00 [ 0.14, 66.53 ]
4 Reticulocytopenia
SCATE 2015 1/11 1/11 1.00 [ 0.07, 14.05 ]
5 Parasite infection
SCATE 2015 1/11 1/11 1.00 [ 0.07, 14.05 ]
0.001 0.01 0.1 1 10 100 1000
Favours hydroxyurea Favours observation
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A D D I T I O N A L T A B L E S
Table 1. Clinical events and markers of response in Jain 2012
Hydroxyurea Placebo P value
Baseline 18 months Baseline 18 months
Clinical events (number of events per participant per year) Clinical events (number
VOC 12.13 (8.56) 0.60 (1.37) 11.46 (3.01) 10.2 (3.24) < 0.001
Blood transfusions 2.43 (0.69) 0.13 (0.43) 2.13 (0.98) 1.98 (0.82) < 0.001
Hospitalisations 10.13 (6.56) 0.70 (1.28) 9.56 (2.91) 9.59 (2.94) < 0.001
Haematological parameters Haematological
Hb (g/dL) 8.1 (0.68) 9.29 (0.55) 8.21 (0.68) 7.90 (0.58) < 0.001
HbF(%) 19.8 (0.9) 24 (5.9) 19.21 (6.37) 18.92 (5.77) < 0.001
Reticulocytes (x10
/mm³)
1.83 (0.96) 1.15 (0.1) 1.73 (0.49) 1.81 (0.67) < 0.001
Leucocytes (x10³ /
mm³)
7.36 (6.03) 6.54 (5.54) 7.26 (4.91) 7.38 (2.85) < 0.001
Platelets (x10³ /
mm³)
1.78 (0.26) 2.01 (0.18) 1.91 (0.21) 2.06 (0.26) 0.28
RBC (x10 /mm³) 2.89 (0.57) 1.98 (0.22) 1.84 (0.47) 3.11 (0.20) 0.05
Total bilirubin (mg/
dL)
2.32 (1.42) 1.10 (0.42) 2.27 (1.28) 2.71 (0.93) < 0.001
Values are mean (standard deviation) P values are calculated using independent t-test.
Hb: haemoglobin
HbF: fetal haemoglobin
RBC: red blood count
VOC: vaso-occlusive crises
WBC: white blood count
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Table 2. Laboratory measurements from MSH 1995
Baseline Hyrdoxyurea Placebo P value
2 years Baseline 2 years 2 years
WBC (10 /L) 12.6 (3.4) 9.9 (3.1) 12.3 (3.2) 12.2 (2.8) 0.0001
Neutrophils (10 /
L)
6.9 (2.4) 4.9 (2.0) 6.7 (2.3) 6.4 (2.0) 0.0001
Platelets (10 /L) 468 (147) 399 (124) 457 (130) 423 (122) 0.12
Hb (g/dL) 8.5 (1.4) 9.1 (1.5) 8.5 (1.2) 8.5 (1.3) 0.0009
PCV (%) 24.9 (4.4) 27 (5) 25.2 (4.0) 25.1 (4.2) 0.0007
MCV (fl) 94 (9) 103 (14) 93 (9) 93 (9) 0.0001
Reticulocytes (10 /
L)
327 (98) 231 (100) 325 (94) 300 (99) 0.0001
HbF (%) 5 (3.5) 8.6 (6.8) 5.2 (3.4) 4.7 (3.3) 0.0001
F cells (%) 33 (17) 48 (23) 33 (17) 35 (18) 0.0001
F reticulocytes 15 (8) 17 (9) 15 (8) 15 (7) 0.0036
Dense cells (%) 14 (6) 11 (6) 14 (7) 13 (7) 0.004
Creatinine (mg/dL) 0.9 (0.3) 1.0 (0.5) 0.9 (0.2) 1.0 (0.5) 0.64
Total bilirubin (mg/
dL)
3.7 (2.4) 2.9 (2.5) 3.7 (2.5) 4.2 (4.6) 0.004
Direct bilirubin
(mg/dL)
0.5 (0.3) 0.4 (0.3) 0.5 (0.4) 0.7 (2.2) 0.08
Aspartate
aminotransferase
44 (23) 39 (20) 41 (21) 43 (27) 0.16
Alkaline
phosphatase
120 (59) 117 (48) 119 (67) 119 (71) 0.71
Values are mean (standard deviation) P values are calculated using independent t-test.
Hb: haemoglobin
HbF: fetal haemoglobin
MCV: mean corpuscular volume
PCV: packed cell volume
WBC: white blood count
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Table 3. Laboratory evaluations from the SWiTCH trial
Outcome Hydroxyurea and
phlebotomy group (n = 67)
Transfusions and
chelation group (n = 66)
P value
HbF (%) 17.9 (92 to 22.9) -0.2 (-0.8 to 0.4) < 0.001
ANC (x10 /L) -3.3 (-5.1 to -1.4) 0.8 (-1.3 to 2.4) < 0.001
Hb (g /dL) 0.0 (-0.7 to 0.7) 0.0 (-0.5 to 0.6) 0.898
HbA (%) -50.9 (-66.8 to -33.7) 0.0 (-12.7 to 6.7) < 0.001
HbS (%) 35.0 (21.7 to 46.2) 0.3 (-7.5 to 12.3) < 0.001
MCV (fL) 19.5 (7.5 to 28.5) 0.1 (-2.0 to 2.5) < 0.001
WBC (x10 /L) -5.4 (-8.1 to -2.2) 0.2 (-2.0 to 2.3) < 0.001
ARC (x10 /L) -149.1 (-231.0 to -19.0) -11.8 (-88.2 to 93.2) < 0.001
Platelets (x10 /L) -83.0 (-171.0 to -8.0) -28.0 (-70.0 to 18.0) 0.0022
Total bilirubin (mg/dL) -1.1 (-1.9 to -0.6) 0.4 (-0.3 to 1.2) < 0.001
LIC (mg Fe/g) -1.2 (-2.8 to 7.2) -2.2 (-5.5 to 4.9) 0.48888
Serum ferritin (ng/mL) -966.0 (-1629.0 to 49.0) 1159.5 (-662.0 to 2724.0) < 0.001
LDH (U/L) -67.0 (-143.0 to 7.0) -8.5 (-74.0 to 74.0) 0.0015
ANC: absolute neutrophil count
ARC: absolute reticulocyte count
Hb: haemoglobin
HbA: adult haemoglobin
HbF: fetal haemoglobin
HbS: sickle haemoglobin
LDH: lactate dehydrogenase
LIC: liver iron concentration
MCV: mean corpuscular volume
WBC: white blood count
Values are median change from baseline and interquartile range. P values are calculated using Wilcoxon rank sum test.
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Table 4. Laboratory evaluations from the SCATE trial
Outcome Hydroxyurea (n = 11) Observation (n = 11) P value
Hb (g/dL) 1.6 -0.5 < 0.0001
MCV (fL) 8.7 1 0.0001
ARC ( x10 /L) 22.7 -33.2 0.76
WBC ( x10 /L) -4.6 1.3 0.07
ANC ( x10 /L) -2.2 1.4 0.05
Platelets ( x10 /L) -76 -35 0.56
HbF (%) 8.9 0.3 0.002
Weight (kg) 2.5 1.8 0.51
Height (cm) 6.8 3.8 0.22
ANC: absolute neutrophil count
ARC: absolute reticulocyte count
Hb: haemoglobin
HbF: fetal haemoglobin
MCV: mean corpuscular volume
WBC: white blood count.
Values are median change from baseline and P values are calculated using Wilcoxon rank sum test.
Table 5. Pregnancies in the MSH Study
Pregnancy Hydroxyurea Placebo
Patients Normal full-term delivery 1 2
Elective termination 2 1
Partners of patients Normal full-term delivery 2 0
Spontaneous abortion 1 0
Still pregnant 0 1
TOTAL 6 4
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WH A T ’ S N E W
Last assessed as up-to-date: 10 April 2017.
Date Event Description
10 April 2017 New search has been performed Six new studies have been added to the review (BABYHUG
2011; Jain 2012; CHAMPS 2011; SCATE 2015; SWiTCH
2012;TWiTCH2016). Summary of findings tables are now
included in the review
10 April 2017 New citation required and conclusions have changed Six new trials have been included in the review (BABYHUG
2011; Jain 2012; CHAMPS 2011; SCATE 2015; SWiTCH
2012; TWiTCH 2016). These include participants with
different genotypes, different disease severities and partici-
pants at risk of primary and secondary stroke. The inclusion
of these new trials has impacted upon the conclusions of the
review
H I S T O R Y
Protocol first published: Issue 3, 2000
Review first published: Issue 2, 2001
Date Event Description
10 November 2010 New search has been performed A search of the Group’s Haemoglobinopathies Trials Register identified 25
new references potentially eligible for inclusion in this review
Fifteen of these were additional references to the BABY HUG study which
is listed as ongoing (Baby Hug 2007a)
Eight references were to the already included MSH trial and provide no
further data or information not already included within the review (MSH
1995).
The remaining two references (each published in abstract form) have been
added to ’Studies awaiting classification’, and we await publication of the
full papers in order to accurately assess eligibility (Jain 2010; CHAMPS
2011a)
5 November 2008 New search has been performed No new trials were identified by the search of the Group’s
Haemoglobinopathies trials Register
1 July 2008 Amended Converted to new review format.
1 February 2008 New search has been performed The search identified four new references.Onewas an additional reference to
the already included MSH 1995 study (Ballas 2006), however, this did not
include any newdata that can be added to the review. A further reference was
to the already excluded De Montalembert 2006 study (De Montalembert
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(Continued)
2006). The third reference was an additional reference to the Baby Hug
2007a study now listed in Ongoing studies (Wynn 2007); and the final
reference has been added to Excluded studies (Silva-Pinto 2007).
In addition, the Plain Language Summary has been updated in line with
latest guidance from The Cochrane Collaboration
1 February 2007 New search has been performed The search identified 12 new references to four studies. Two of the new
references were additional references to the already included MSH 1995
study; however, no further data have been included in the review. Seven
of the references were to one study, which is listed in ’Studies awaiting
assessment’ (Baby Hug 2005). The remaining three new references have
been excluded (De Montalembert 2005; Voskaridou 2005; Ware 2006).
1 February 2006 New search has been performed The search identified one new reference (Charache 1993) which is an ad-
ditional reference to the already included MSH 1995 trial. This reference
provided no additional data.
Ashley Jones became lead author in September 2005 and acts as guarantor
of the review
1 November 2004 New search has been performed The search identified one new reference to the already includedMSH 1995
trial: Orringer EP, Jones S, Strayhorn D, Hoffman E, Parker J, Greenberg
CS. The effect of hydroxyurea (HU) administration on circulating d-dimer
levels in patients with sickle cell anemia [abstract]. Blood 1996;88(10 Suppl
1):496a
Following on from the inclusion of this reference, a further outcome has
been added to the review: cost effectiveness of hydroxyurea
1 November 2003 New search has been performed Two additional references to the already included MSH 1995 study have
been incorporated into the review
1 February 2002 New search has been performed Quality of life data, presented in an abstract by Terrin (Terrin 1999), which
reports on the MSH study (MSH 1995), has now been incorporated into
the review
C O N T R I B U T I O N S O F A U T H O R S
Original review (2001)
Sally Davies (SD) and Ade Olujohungbe (AO) conceived review and evaluated studies. SD drafted review.
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2005 (minor) update
SD drafted review (with input from AO), but stepped down as lead author in September 2005 (remained as co-author). Ashley Jones
(AJ) became lead author in September 2005 and assisted in drafting the update and now acted as guarantor of the review.
2010 (minor) update
AJ drafted the update with input from SCD and AO. AJ acts as guarantor of the review.
2017 (major) update
SJN became lead author in 2016 and led the current update on screening, data extraction, risk of bias assessment, analysis, summary
of findings table and drafting results and discussion.
JH provided clinical interpretation of the review, drafted text of the discussion and commented on all sections of the review.
AJ extracted and data and drafted text as well as commenting on later draft versions.
SD stepped down as co-author.
D E C L A R A T I O N S O F I N T E R E S T
Sarah Nevitt: none known.
Ashley Jones: none known.
Jo Howard: no declarations in relation to the use of hydroxyurea. In general, has undertaken consultancy for Bluebird Bio; AesRx;
and Global Blood Therapeutics. Her institution has the following grants: NIHR grant for the POMS trial (prevention of morbidity in
SCD); and an NIH grant for natural history in stroke in SCD (pending).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The final secondary outcome (cost effectiveness of hydroxyurea) has been added at the 2005 update of this review but removed in the
2017 update of the review as economic methods which are outside the scope of Cochrane reviews are required to truly reflect cost-
effectiveness of an intervention.
The protocol stated that odds ratios would be used as the measure of treatment effect for dichotomous data, however on reflection, we
felt it more appropriate to present risk ratios in preference to odds ratios (OR), as odds ratios give an inflated impression of the size of
effect where event rates are high, as is the case of these studies.
2017 update: definition of primary outcome ’Pain Alteration’ updated to better reflect the measures which are suitable for inclusion
under this outcome.
2017 update:We changed the definition of the outcome: “Any reported adverse effects or toxicity of hydroxyurea recorded” to “Reported
adverse effects or toxicity” as it is difficult to distinguish between adverse reactions (i.e. adverse events which are definitely drug related)
and other adverse events which may be sickle or transfusion related. Where reported in study reports, we have separated reported
adverse effects into drug-related, sickle-related, transfusion-related etc.
In the 2017 update of the review, serious adverse events reported in included studies (whether treatment-related or not) were included
under the definition of primary outcome ’Life-threatening illness.’
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antisickling Agents [∗therapeutic use]; Hemoglobin SC Disease [∗drug therapy]; Hydroxyurea [∗therapeutic use]; Randomized Con-
trolled Trials as Topic
MeSH check words
Humans
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